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A large part of the genomic arrangement regulating the immune system is 
located in the Major Histocompatibility Complex (MHC) region on 
chromosome 6p21.31. Human leucocyte antigen (HLA) genes, which encode 
the antigen presenting molecules, are located in MHC class I and II, while the 
MHC class III region contains non-HLA genes, e.g. butyrophilin-like protein 
2 (BTNL2), tumor necrosis factor (TNF) and complement C4. Most genes in 
the MHC region play an important role in susceptibility to autoimmune and 
infectious diseases.  
Sarcoidosis is a complex granulomatous disorder with varying a clinical 
presentation. A multitude of studies have reported strong associations 
between genes in the MHC and sarcoidosis. The structure of the MHC is 
characterized by a high degree of polymorphism, due to population-specific 
and highly conserved extended haplotypes, leading to a complicated pattern 
of linkage disequilibrium (LD). This makes dissecting disease associations 
within individual MHC genes difficult.  
The primary aims of this Study were to study the overall polymorphism of 
the MHC region in Finnish subjects, to investigate MHC as a susceptibility 
locus for sarcoidosis and to find predictive markers for the prognosis of the 
disease.  
In Study I, extended MHC haplotypes covering genes within MHC class I 
(HLA-A, -B), MHC class II (HLA-DRB1, -DQB1 and –DPB1) and MHC class 
III (e.g. TNF and BTNL2) were constructed and LD between the genes 
studied in a Finnish population sample. We discovered that the extended 
MHC haplotypes could be grouped, based on a similar functional variant (e.g. 
truncating protein) or a similar structure of the peptide binding site. In Study 
II, we replicated a previously reported HLA-DRB1*03:01 association with a 
favourable prognosis of sarcoidosis in Finland (P=0.007, OR=2.7). Using the 
extended MHC haplotype approach, we detected novel and independent 
variants associated with sarcoidosis (HLA-DPB1*04:02; P=0.003, OR=0.48) 
or the disease course of sarcoidosis (HLA-DRB1*04:01-DPB1*04:01; P=0.02, 
OR=3.07). In Study IV, we explored four genes in the MHC class III region 
(LTA, TNF, AGER, BTNL2) and HLA-DRA, and performed a replication and 
meta-analysis in four European populations. After adjusting for sex, 
population stratification and HLA-DRB1 alleles, four SNPs in the HLA-
DRA/BTNL2 region were associated with non-Löfgren sarcoidosis; the 
strongest signal association was detected with rs3177928 (1.79x10-7, 
OR=1.90). In this Study, we also addressed guidelines for disease association 
studies dealing with immunogenetic data.  
The results of the extended MHC haplotype analysis discovered a unique 
haplotype admixture in the Finnish population, which may have implications 
to MHC-related disease associations. Our sarcoidosis study provided new 
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insights to predicting the disease prognosis, with different distributions of 
MHC variants associating different patterns of progression, further 
promoting the importance of MHC region in sarcoidosis predisposition. 
Especially, the region covering the genes BTNL2 and HLA-DRA warrants 
further studies in larger samples and in different ethnic groups. To conclude, 
this Study showed the importance of studying extended MHC haplotypes in 
well-characterized samples, in order to understand the complex MHC 
structure and to distinguish variants’ associations with the trait. 
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aa  amino acid  
AGER (RAGE) receptor for advanced glycation endproducts  
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CI  confidence interval 
CNV  copy number variation 
CTins  CT insertion mutation 
CWD  common, well documented 
C4  complement component 4 
C4A  acidic isotype of complement component 4 
C4B  basic isotype of complement component 4 
DNA  deoxyribonucleic acid 
DZ  dizygotic 
ECG  electrocardiography  
EFI  European Federation for Immunogenetics 
ENCODE  the Encyclopedia of DNA Elements 
ERAP1  endoplasmic reticulum aminopeptidas 
eQTL  expression quantitative trait locus  
FIMM  Institute for Molecular Medicine Finland 
GD  Graves’ disease 
GWAS  genome-wide association study 
HARPS  Ambiguity Resolving primers  
HLA  human leucocyte antigen  
HSCT   hematopoietic stem cell transplantation  
HWE   Hardy Weinberg equilibrium 
HVR   hypervariable regions 
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h2  heritability (narrow-sense) 
LD  linkage disequilibrium 
LS  Löfgren syndrome 
LTA   lymphotoxin alfa 
MAF  minor allele frequency 
mRNA  messenger ribonucleic acid 
MHC  major histocompatibility complex 
miRNA  microRNA 
MS  multiple sclerosis 
MZ  monozygotic  
NGS   next-generation sequencing 
NL  non-Löfgren syndrome 
NLR  non-Löfgren syndrome, resolved sarcoidosis 
NLP  non-Löfgren syndrome, persistent sarcoidosis   
OR  odds ratio 
RA  rheumatoid arthritis 
RT-PCR   realtime-PCR  
PBS  peptide-binding site 
Pc   corrected P value 
PCR  polymerase chain reaction 
PCS  protein coding site 
P9  peptide-binding pocket nine 
S-ACE   angiotensin-converting enzyme 
SBT  Sequence-Based Typing 
Ser  serine 
SSO   Sequence-Specific Oligohybridization 
SSP  Sequence-Specific primer 
QC   quality control 
qPCR  quantitative polymerase chain reaction (PCR) 
SLE  systemic lupus erythematosus 
SNP  single nucleotide polymorphism 
tag-SNP  tagging-SNP 
TCR  T cell receptor 
TF  transcription factor 
TID  type I diabetes 
TNF  tumor necrosis factor 
TFIID  transcription factor II D 
χ2  Chi-square  
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1 INTRODUCTION 
The most polymorphic genetic region in the human genome, the major 
histocompatibility complex (MHC), has been associated with several 
inflammatory (e.g. sarcoidosis) and autoimmune diseases [e.g. type I diabetes 
(T1D) and multiple sclerosis (MS)], as well as graft failure [1]. The MHC 
region has a complex allelic structure with extended linkage disequilibrium 
(LD) and polymorphism, reviewed in [2]. The genes that encode the cell-
surface antigen-presenting proteins, the human leucocyte antigen (HLA) 
genes, are located at the MHC region among many other genes related to 
immune response. The main role of the immune system is to recognize and 
distinguish self from non-self [3]. The previous studies on MHC region have 
increased our knowledge of the genetic risk factors for autoimmune and 
infectious diseases, shed light understanding the disease pathogenesis, 
identification of individuals with high risk, disease prognosis and suggested 
therapeutic approaches.  
One of the MHC-related diseases is sarcoidosis. Sarcoidosis is a systemic 
disease of unknown etiology and with varying clinical course [4]. Based on a 
nation-wide survey performed in 1984, the crude prevalence of sarcoidosis in 
Finland was 30/105 and the annual incidence 11/105 [5,6]. Sarcoidosis is a 
complex disease, with interactive effects from the environment and multiple 
genes. Both linkage and association studies, including the recent genome-wide 
association studies (GWASs), have shown a strong role for MHC in 
susceptibility to sarcoidosis [7] with distinct disease phenotypes and 
populations. To explore the prognosis of sarcoidosis, the immunologically 
important MHC region offers opportunities to discover disease phenotype 
specific gene variants.  
This study aimed to characterize the general polymorphism of the MHC 
region in Finnish subjects and in sarcoidosis patients to discover novel risk 
factors and to improve the prediction of disease course. Overall, we set out to 
understand the complexity of the MHC data to suggest guidelines on how the 
MHC disease association studies should be conducted, taking into account the 
special challenges in immunogenetic data analysis: the highly polymorphic 
nature of the MHC region, population stratification, and the resulting 
statistical issues. 
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2 REVIEW OF THE LITERATURE 
2.1 THE HUMAN GENOME 
 
The international scientific collaboration project, the Human Genome Project, 
launched the first draft of the sequenced human genome in the beginning of 
the 21st century [8,9]. The project estimated the number of protein-encoding 
genes to be approximately 21 000, coded by sequence that represents only a 
small fraction of the human genome (1.1-3 %) [10]. The majority of the human 
genome consists of functional non-coding regions, such as micro-RNA, 
repetitive sequences (e.g., tandem repeats associated with various diseases 
[11]), gene expression regulators, and regions of unknown function. The 
molecular basis of inheritance, the deoxyribonucleic acid (DNA), is located in 
the chromosomes at nucleus of every cell in the body (except mature red blood 
cells). Typically, the human genome consist of 22 pairs of autosomal 
chromosomes and two sex chromosomes (XX or XY), with one half of the pair 
of sister chromosomes inherited from the mother, the other one from the 
father.  
 
Figure 1 From chromosomes to protein. Protein-coding genes contain segments called the 
promoter, a number of introns and exons and the 3’ region. Before mRNA (the 
transcript of the gene sequence) is translated into a protein at the ribosomes, it is 
processed in the nucleus as introns are removed and exons spliced together.  
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The structure of genes can be roughly divided into four segments; 
promoter, exons, introns and downstream regulatory regions (3’ end). The 
promoter region in the 5’ prime side of the gene acts as a gene regulator 
binding transcription factor II D (TFIID) [12,13], and consists of a conserved 
TATA-box and a variable CpG-rich site [14]. Figure 1 shows the key factors in 
transcription and translation. Transcription of DNA to RNA occurs from 5’ to 
3’ prime end. Exons comprise the gene code that will be transcripted into pre-
messenger ribonucleic acid (pre-mRNA). The introns, which are not involved 
in the protein formation, are spliced off from the pre-mRNA to form mRNA. 
Translation takes place at the ribosomes, where transfer RNA (tRNA) 
transfers amino acids to form the polypeptide chain based on the mRNA code 
(corresponding with the DNA coding strand) (Fig. 1) [8,9].  
2.1.1 GENOME REGULATION  
The regulation of gene expression is a complex and strictly regulated process 
containing various factors and levels of regulation. Furthermore, the protein 
coding genes are differentially expressed and regulated in different cells. Any 
stage of gene regulation and expression (chromatin domains, transcription, 
RNA transport from nucleus to cytoplasm, translation, mRNA degradation) 
can be modified. Particular genes, involved e.g., in DNA replication and 
repair, are continuously expressed. However, the most genes are regulated 
occasionally and “turned off” by histone proteins that are tightly bound to the 
DNA [15]. In order for transcription to take place, the DNA needs to be 
unwound, e.g., by histone modifications. In addition, modifier genes that 
affect the expression of some alleles, external environmental factors, 
transcription factors (TFs) and microRNA (miRNA) regulate gene expression 
[15,16]. In addition to the promoter region, regulatory features exist, including 
the 5’ untranslated region that controls the initiation of translation and 
enhancers that can be physically situated far away from the gene, [17]. 
Polymorphisms in the protein coding site (PCS) or regulatory elements (e.g., 
transcription factor binding sites) can alter the structure of the gene product 
or its function [18,19]. The gene regulation can be studied e.g., by exploring 
SNPs that associate with gene expression [expression quantitative trait locus 
(eQTL)] [20,21]. 
In recent years, the Encyclopedia of DNA Elements (ENCODE) project has 
discovered novel features of the human genome (e.g., novel non-coding RNA, 
novel transcription promoters and novel gene isoforms) that provide new 
insight into the concepts of gene and gene regulation [15,22-24]. Furthermore, 
the ENCODE project has suggested that at least 80% of the genome has some 
biochemical function (e.g., transcription or DNA regulation) in at least one 
cell type [22]. Interestingly, the ENCODE project has also estimated that over 
60% of the genome is transcribed into RNA [15], although only a small 
fraction of the genome encodes proteins. The ENCODE project shows that the 
previously believed junk DNA is actually functional: The most of the non-
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coding DNA is involved in gene’s regulation suggesting a far more complex 
regulation process than previously thought [25]. 
2.1.2 GENETIC VARIATION  
International consortia, including the 1000 Genomes Project [21,26], the 
International HapMap Project [27] and the ENCODE consortium [25] have 
explored the human variation by studying the rare variants, ancestral 
haplotypes and functional regions of the human genome, respectively, to 
understand the variance and function of the genome and its relation to the 
traits. In general, genetic variation involves changes to the base sequence of 
DNA. The average rate for de novo variation per generation is 1.20 × 10-8 per 
nucleotide which corresponds to approximately 70 novel single nucleotide 
variations per genome per generation [28]. It has been speculated that most of 
the polymorphism in the genome is rare, with a minor allele frequency (MAF) 
<1%.  A polymorphism may involve a single base change, called a point 
mutation, or larger sections of DNA through deletions, insertions (Fig. 2), or 
translocations [25].  
 
Figure 2 Monogenic traits are the result of variation in a single gene. Complex traits are the 
result of interplay between numerous genetic susceptibility factors and environmental 
factors. SNPs are the most common type of variation. The structural variations (e.g., 
microsatellites or insertion-deletion polymorphism) affect the length of the sequence. 
The alleles are the variants of a DNA sequence at locus (physical location of the 
variant), which can be bi-allelic (SNP) or multiallelic (HLA genes, copy number 
variations). 
The most typical example of sequence variation is the single nucleotide 
polymorphisms (SNP) that are common in the genome, and are typically 
biallelic. Copy number variation (e.g. microsatellites) and insertion-deletion 
polymorphisms represent structural variation, which occur at much lower 
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or the loss of one or more nucleotides. A silent mutation does not have any 
effect on the resulting protein.  In case of splice site mutation, an altered 
mRNA sequence is formed as the splicing of introns are damaged resulting in 
a non-functional protein [21]. 
Contradictory to monogenic traits, which are typically affected mainly by 
only a few genes, various traits are complex, with both genetic and 
environmental factors being needed for the occurrence of the trait (Fig. 2). 
The concepts of sequence variation, monogenic and complex disorders and 
allele are highlighted in Fig. 2. The effect of the alleles can be dominant (only 
one copy is required for a particular trait to be expressed), recessive (two 
copies of the allele are required for the trait to be expressed) or co-dominant 
(two dominant alleles both expressed). A genotype is referred to as the genetic 
makeup of a person, while a phenotype is the manifestation of the genotype 
(Fig. 2). When the same genotype leads to the same disease phenotype, in case 
of many monogenetic diseases, the penetrance is complete. However, if the 
penetrance is incomplete, all the allele carriers do not express the trait. 
Genetic heterogeneity means that different genotypes in different loci (in a 
same gene or different gene) result in the same outcome, phenotype. 
Contrary, different disease phenotypes can be the result of the same variation 
or different variation in the same gene [21]  
Epigenetics can be defined by events that alter the phenotype but do not 
change the nucleotide sequence, such as posttranslational modifications of 
histones, the methylation of CpG islands, phosphorylation, and the expression 
of noncoding RNAs. Epigenetics can be considered to be a link between a 
genotype and a phenotype and contributes to the development of complex 
diseases. Furthermore, the mutation in nucleotide sequence may cause failure 
in the methylation sites and environmental triggers, such as carcinogens, may 
permanently alter epigenetic patterns [30-32]. 
Heritability is a mathematical estimate, which is defined as a degree of 
variation in a trait that can be explained by genetic factors [33]. Heritability is 
dependent on the population studied, typically measured as the narrow-sense 
heritability (h2) and expressed as percentage value. Twins are typically studied 
for heritability estimates: On average the MZ twins share the same genome 
and the DZ twins share genes like normal siblings share (50% of the genome). 
If a disease is more correlated in MZ than in DZ twins, the genetic factors are 
the likely to influence the aetiology of the disease [33,34]. For example, the 
heritability (h2) of the height in the Western countries is roughly 80%, 
indicating that 20% of the height variance can be explained by the 
environmental factors between the individuals (reviewed in [35]). 
2.2 THE IMMUNE SYSTEM 
The role of the immune system is to protect the host organism from 
potentially pathogenic agents or substances, including bacteria, viruses, 
toxins, or cancer cells, by recognizing harmful non-self-antigens and altered 
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self-antigens immediately with the innate immune system and with antigen 
specific adaptive immune response (Fig. 3). The structure and development of 
the immune system is unique for every individual. Numerous cell populations, 
mostly leucocytes, react against potential antigens through innate or by 
adaptive immunity mechanisms. Most immune system cells are T and B 
lymphocytes (i.e., T and B cells) or macrophages and neutrophils (reviewed in 
[36,37]. 
 
Figure 3 The immune system, typically divided into two categories, the innate and the 
adaptive immunity, operates through complex networks and pathways to defend 
the body against attacks by foreign invaders. Innate and adaptive systems work 
together to eliminate pathogens. The innate immunity system is quick in 
response to nonspecific microbe-specific molecules that are recognized by a 
given pattern-recognition receptor (PRR; e.g., toll-like receptors). The innate 
immunity uses phagocytosic cells, which release inflammatory mediators, natural 
killer (NK) cells and molecular components such as those involved in the 
complement cascade. The innate responses do not improve on repeated 
exposure to the antigen, as the adaptive responses do. The adaptive immune 
system is antigen-specific, where the antigen-presenting cell (APC) presents the 
particular antigen to lymphocytes. The adaptive immune systems have two 
adaptive mechanisms: cell-mediated immunity with T and B cells and humoral 
immunity with antibodies produced by plasma cells and cytokines. [36] 
The innate system is among the first cells to encounter pathogens inside 
the physical protective barriers, skin and mucous membranes. The innate 
system recognizes non-self-structures typical to many pathogens with non-
antigen specific pattern-recognition receptors (PRR), e.g., toll-like receptors 
[38]. In the adaptive immune system, the T cells are the key element in 
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main effector of humoral responses. TCRs are transmembrane heterodimer 
molecules [39]. Antigen presenting cells (APC, e.g., dendritic cells and 
macrophages) bind intracellulary processed antigens and present antigen in 
the MHC molecule that is on the surface of the cell. The first contact with the 
pathogenic agents differentiates the naïve CD4+ T lymphocytes (Th0) into 
various populations, such as T helper (CD4+ Th1, Th2, Th17) or regulatory T 
cells (CD4+ Tregs), later regulated by epigenetic mechanisms via cytokine 
production and presence of certain cell types. The CD8+ T lymphocytes are 
cytotoxic T cells [40]. When the B cells recognize an antigen with the B cell 
receptor (BCR), B cells differentiate into plasma cells that secrete antibodies, 
which in turn destroy pathogens by activate complement cascades and 
recruiting other cells. Furthermore, each B lymphocyte clone can produce 
particular circulating antibodies (immunoglobulins IgA, IgE, IgG or IgM). The 
immunoglobulins are glycoproteins and all the classes have different functions 
(reviewed in [36]. 
Autoimmune disease may develop as a result of altered balance between T 
regulatory lymphocytes and self-reactive T lymphocytes. The causality in 
autoimmune, and as well as inflammation traits, is the incorrect action of the 
immune system against self-tissue that should be normally tolerated. 
Typically, the negative selection prevents autoimmunity, removing 
autoreactive B lymphocytes in bone marrow and autoreactive T lymphocytes 
within the thymus. In addition, peripheral tolerance removes autoreactive 
lymphocytes based on incomplete activation signals. The autoimmune 
diseases can be classified by the mechanism of tissue damage. In systematic 
autoimmune diseases, such as systemic lupus erythematosus (SLE) [41], 
various tissues are affected and the autoimmunity is mediated both by T and B 
lymphocytes [42]. In T-cell-mediated diseases, multiple sclerosis (MS) or type 
I diabetes (T1D), a particular tissue is attacked by the autoreactive cells [43-
46]. Specifically, in the case of T1D, the immune system does not tolerate self-
pancreatic β-cells in the Islets of Langerhans resulting in loss of insulin 
secretion [47,48].  
 
2.3 THE MAJOR HISTOCOMPATIBILITY COMPLEX 
(MHC)  
The human MHC region is located on the chromosomal region 6p21.31, 
spanning approximately 4 megabases of DNA. The first human MHC 
sequence was released in 1999 [49]. The MHC contains over 200 genes, which 
makes it one of the most gene-rich regions in the genome. In addition, 
compared with other genomic regions, the MHC shows the most variability 
characterized by high linkage disequilibrium (LD), and is rich in 
recombination hotspots and population specific features [50]. The variability 
of the MHC region is suggested to be strongly influenced by selection, e.g., 
pathogen-driven balancing selection [51,52]. 
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Genetic structure of the human MHC region can be roughly divided into 
three sections: the MHC class I, II and III (Fig. 4). It has been speculated that 
the region was developed from a block of duplicated immune systems [50,53]. 
The traditional Human leucocyte antigen (HLA) genes, HLA-A, -B and –C, are 
located in the MHC class I (i.e., HLA class I) and HLA-DRB1, -DQB1 or -DPB1 
are located in MHC class II (i.e. HLA class II) [54].The structure of MHC class 
I and II molecules is presented in Fig 4.  
 
Figure 4 The human MHC region in chromosome 6 encodes antigen presenting HLA 
molecules (in MHC class I and II) and critical mediators of innate immunity and many 
non-immune genes in MHC class III genes e.g., BTNL2 (butyrophilin-like 2), TNF 
(tumor necrosis factor), complement C4, AGER (advanced glycosylation end product 
receptor).  The HLA class I molecules consist of an α-subunit that includes the 
polymorphic peptide-binding cleft (formed by α1 and α2) and of the non-polymorphic 
β-subunit (β2) which is encoded by the beta-2 microglobulin (B2M) gene on 
chromosome 15[58]. The MHC I α3 domain spans though plasma membrane and 
interacts with T cell receptor (TCR). The HLA class II molecules are heterodimers 
formed by the α-subunit (encoded by HLA-DRA, -DQA1 or -DPA1) and by highly 
polymorphic β-subunit (encoded by HLA-DRB1, -DQB1 or –DPB1). In HLA class II, 
the antigen binding cleft is encoded by α1 and β1 domains (reviewed in [59]). 
A sequence of the newly defined xMHC was completed in 2003 as part of 
the sequencing of the entire human chromosome 6 and now covers a total of 
7.6 Mb on the short arm of this chromosome. The extended MHC (xMHC; 7.6 
Mb) was sequences in 2003 and includes the traditional HLA as well as the 
genes outside of MHC class I and class II (e.g. MHC class III region) [55]. 
Roughly, the xMHC can be divided in to the extended MHC class I 
(HIST1H2AA to MOG; 3.9 Mb), the classical MHC class I (C6orf40 to MICB; 
1.9 Mb), the classical MHC class III (PPIP9 to NOTCH4; 0.7 Mb), the classical 
MHC class II (C6orf10 to HCG24; 0.9 Mb) and the extended MHC class II 
(COL11A2 to RPL12P1; 0.2 Mb) (reviewed in [50]). The MHC class III region 
MHC)class)II)




















  19 
located between the MHC classes I and II is the most gene rich region of the 
MHC. There are three types of genes in the MHC class III region; immune 
response related genes (e.g., TNF), non-immunological genes, and genes that 
are not expressed (pseudogenes). The genes in the MHC class III are typically 
tightly linked with other MHC genes with potential functional interaction with 
the HLA genes [54,56,57].  
The HLA genes are differentially expressed in different cell populations. 
The HLA class I molecules are expressed on most nucleated cell surfaces and 
present intracellular pathogen antigens to CD8+ cytotoxic T cells. HLA class I 
molecules bind short peptide fragments (the majority of these peptides are 
length of 9) generated in the cytosol by proteasomal degradation [60,61]. 
These short peptides anchor into the end of HLA class I peptide-binding 
groove[62]. If the complex activates, the presenting cell is destroyed by 
apoptosis.  
Each HLA class I molecule is able to bind between 1000 and 10 000 
peptides and each HLA class II molecule to bind approximately 2000 peptides 
[63]. The MHC class II molecules are presented on antigen presenting cells 
such as e.g., dendritic cells. The peptide binding-groove of the HLA class II 
molecules is open that enables variable size of peptides to bind into the 
molecules (typically size of the peptides are 8-15 amino acids) [64]. HLA class 
II molecules typically bind peptides from endocytosed proteins and present 
the peptides to CD4+ helper T cells. In addition, HLA class II molecules 
regulate self-tolerance immunity presenting purified peptides from class II 
molecules that are derived from cytosolic self-proteins [65]. The activation of 
the MHC class II CD4+ complex is presented in Fig. 3 [50]. 
2.3.1 MHC DIVERSITY BETWEEN SPECIES 
In humans, the MHC region is often referred as the human leukocyte antigen 
(HLA) region and the antigen processing and presenting genes are called the 
HLA genes [49]. Primate species, especially higher primates (chimpanzees 
and gorillas) have similar MHC structures compared with humans. However, 
the largest differences between human and higher primates are the position of 
polymorphism, the unique HLA-A –related gene in chimpanzees and the 
distict variability in MIC-genes [66].   
A detailed genetic structure of MHC region has been published several 
vertebrates such as, mouse (in chrom. 17; [67], rat (RT1 complex in Chr 20; 
[68], dog (DLA complex in Chr 12; [69]) and chicken [70]. The function of 
MHC and the architecture of the antigen-presenting molecules are conserved 
between species [71]. However, in other species the MHC region (especially 
MHC class I) differs extensively in both the number of genes and their 
arrangement [66].  For example, the MHC B-complex in chicken encodes only 
two genes each in class I and class II [72], and the mouse and rat MHCs 
[73,74]lack MIC-related genes altogether. In addition, MHC genes are 
regulated differentially between species; for example, the mice MHC class II 
molecules are not expressed on the cell surface of the T cells [75]. 
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Translocation of the MHC in zebrafish shows the extent of the variation: MHC 
class I, II, and III are not linked as a complex as they are in many other 
vertebrates, and the structure of MHC class II varies extensively [76,77]. 
2.3.2 COMPLEX NOMENCLATURE OF THE HLA ALLELES 
The HLA genes show extensive polymorphism and distinct variety among 
population. In contrast to the non-HLA genes, which have a modest number 
of alleles, a particular HLA gene can have up to 3000 alleles. There are some 
exceptions, e.g., HLA-DRA, which has only seven identified alleles. HLA-B 
and HLA-DRB1 are the most polymorphic HLA class I and class II genes, 
respectively (IMGT/HLA database [78], Fig. 5). To compare, number of the 
canine MHC (DLA) alleles are 100 for DLA-DRB1, 26 for DLA-DQA1 and 60 
for DLA-DQB1[79]. 
The HLA alleles are co-dominantly inherited, i.e. both alleles are expressed 
unless a mutation occurs. The HLA null alleles are normally not expressed at 
the cell surface (as a serologically detectable product) due to variation in the 
sequence e.g., frameshift mutation leading into premature stop (HLA-
A*01:04N) [80].  The number of alleles has increased dramatically in recent 
years (Fig. 5) [78]. However, only 10 % of these alleles have been fully 
sequenced and can be described as common, well documented (CWD) HLA 
alleles [81].  
 
Figure 5 Statistics of HLA class I and class II alleles (Release 3.14/2013). The number of HLA 
alleles in the IMGT/HLA database release from 1998 to 2013. 
(http://www.ebi.ac.uk/imgt/hla/). Several alleles can encode the same protein. 
Null alleles are not expressed on the cell surface. [78] 
Gene Alleles Proteins Null alleles
HLA class I
HLA-A 2,432 1,740 117
HLA-B 3,086 2,329 101
HLA-C 2,035 1,445 57
HLA class II
HLA-DRA 7 2 0
HLA-DRB1 1,375 1,020 27
HLA-DQA1 51 32 1
HLA-DQB1 459 303 13
HLA-DPA1 37 19 0
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The polymorphic HLA genes are classified according to the HLA 
nomenclature that is standardized and regularly updated by an international 
committee [IMGT/HLA Database (http://www.ebi.ac.uk/imgt/hla/)], and 
describes the gene-wide haplotypes of particular HLA gene [78,82,83]. 
Initially, the characterization of the HLA loci was needed for transplantation 
purposes. As presented in Fig. 6, the allele designations for each gene (e.g., 
HLA-DRB1*) are a set of numbers separated by digits. The first field (first two 
digits) describes the allele family and the low-resolution allele, typically 
corresponding to serological antigens (e.g., HLA-DRB1*01). The following 
fields describe the amino-acid sequence of the gene product (HLA-
DRB1*01:01; high-resolution allele) and any synonymous nucleotide 
substitutions in exons (HLA-DRB1*01:01:01). The last fields describe the 
polymorphism observed in the introns or in the 5′ and 3′ untranslated regions 
(HLA-DRB1*01:01:01:01). The suffix at the end of the digits describes the 
level of protein expression, (“N” i.e. null allele). HLA genotyping with “high 
resolution” (typically referred as typing with 4-digits, e.g. HLA-DRB1*01:01 
and resolving polymorphism in the peptide binding region) produces lower 
levels of ambiguity than typing with “low or medium resolution” (two-digit 
resolution, HLA-DRB1*01) [78,84].  
 
Figure 6 Complex HLA nomenclature [Adapted from IMGT/HLA Database 
(http://www.ebi.ac.uk/imgt/hla/)]. 
2.3.3 HLA TYPING METHODS  
Traditionally HLA alleles were detected using serological techniques with the 
HLA-specific alloantisera and/or monoclonal antibodies. After the 
development of the DNA sequencing technology in the 1980s, HLA 
laboratories have mainly utilized DNA-based typing techniques, such as 
Sequence Specific Oligohybridization (SSO), Sequence Specific primer (SSP) 
typing and Sequence Based Typing (SBT). Typically, the polymorphisms in 
regions that encode the polymorphic peptide-binding site of the HLA 
Serological)group) ) ) ) ) ) ) ) ) ) ) )DR1)
Two;digit)resolu'on/low)or)medium)resolu'on) ) ) ) )DRB1*01)
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molecules are genotyped, specifically exon 2 for MHC class II loci, and exons 2 
and 3 for MHC class I loci [84,85]. 
The genotyping of HLA genes and allele calling is challenging as the HLA 
alleles may differ only by a single base, and homological segments and 
pseudogenes complicate alignment with the reference sequence. The choice of 
HLA allele typing method depends on various aspects, such as how deep a 
resolution of the HLA allele is needed, how many samples are typed 
simultaneously and the cost of the method. With SBT and SSO, high 
throughput HLA typing can be performed. Luminex technology uses the SSO 
method where the DNA is hybridized by beads carrying an SSO probe. Fast 
but laborious, SSP typing uses many different allele or allele group-specific 
PCR primers in multiple PCR reactions. With SBT, the complete nucleotide 
sequence at the selected gene region is sequenced, offering a possibility to 
identify novel HLA alleles, which is not possible with SSO or SSP. However, 
the result of SBT, a hemizygous sequence, requires specialized allele 
assignment software for sequence alignment with the HLA allele reference 
library (IMGT database) [78].  
In case of allele ambiguity (i.e., multiple allele combinations have the same 
sequence and the phase is not known), either heterozygous Ambiquity 
Resolving primers (HARPS) or sequencing of additional exons or introns are 
needed.  By sequencing multiple exons of HLA genes, the potential amount of 
ambiguities increases. One approach for addressing allele ambiguity is to use 
the G groups (i.e., all class II alleles that share the same exon 2 nucleotide 
sequence and class I alleles that share the same exon 2 and 3 sequence) and 
the P groups (i.e., all alleles that encode the same peptide-binding region). 
The HLA allele ambiguities can also be resolved by using population-specific 
HLA allele distributions, known HLA haplotypes, and categorization of the 
HLA alleles into common and rare [78].  
Today, newer HLA typing techniques are used in research, including high-
throughput microarrays, HLA imputation and next-generation sequencing 
(NGS). It is challenging, even impossible, to design probes for HLA-alleles in 
high-throughput microarrays to cover both the ethnic polymorphism and 
within gene polymorphism of the HLA [86]. Thus, microarray-based SNP 
typing is not suitable for typing the HLA genes directly. However, SNPs [i.e. 
tagging-SNP (tag-SNP)] located away from the hotspots have been 
successfully used for imputing the traditional HLA alleles (or amino acid 
variants), if the SNP is in strong LD with a particular HLA allele [86]. 
Imputation is a statistical process where the SNP genotypes are used to infer 
missing HLA allele data. Furthermore, a tag- or proxy SNP represents the 
surrounding region, thus therefore only the SNP need to be genotyped. The 
imputation of HLA alleles has been shown to be a valuable tool for screening 
certain HLA alleles, e.g., HLA-B*57:01 [87,88] and HLA-DQB1 alleles for 
celiac disease [89] (Table 1), and boosted further development of imputation 
algorithms for GWASs (e.g. HLA*IMP [90,91], HIBAG [92], SNP2HLA [93]). 
The importance of independent validation of tag-SNPs in another population, 
and the use of population-specific reference panels for GWAS imputation is 
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important [82,89,94], given the population-specific LD patterns and 
polymorphisms in the MHC region, 
 
Table 1. Tag-SNPs for DQ-DR molecules associated with celiac disease [82,89,94]  
tag-SNP(s) DQ    DQ-haplotype DRB1 allele 




DQ2.2 DQ2 heterodimer in trans DQA1*02:01-DQB1*02:02 DRB1*07:01 
rs4639334 DQ7 DQ2 heterodimer in trans DQA1*05:05-DQB1*03:01 DRB1*11/*12 
rs2187668 DQ2.5 DQ2 heterodimer in cis DQA1*05:01-DQB1*02:01 DRB1*03:01 
 
NGS can be utilized for whole-genome or RNA-sequencing; however, the 
method is still too expensive for large-scale studies. NGS offers major 
advantages, including the absolute resolution of the alleles in long HLA 
haplotypes with phase information and the lack of ambiguous allele 
combinations [95]. However, the short reads in NGS (ranging from 25 to more 
than 500 bases) are typically insufficient for unambiguous assembly [96]. 
Indeed, large-scale reference panels for multiple global populations are 
warranted, as the de-novo assembly still needs improvement [2,97]. In 
addition, NGS has been hampered with structural variation (i.e., copy number 
variation and repetitive sequences) [98]. The four major sequencing 
platforms, Roche GS 454 FLX, Illumina MiSeq/HiSeq, PGM Ion Torrent and 
Pacific Biosciences, have different approaches depending on the instruments 
used, but with specialized analytical tools (e.g., Conexio Genomics (Fremantle, 
Western Australia, Australia) and GenDx (Utrecht, The Netherlands)), the 
genotyping results have been shown to be alike.  Interestingly, a recent 
publication showed that the nanochannel genome mapping approach (with 
Illumina’s HiSeq 2000) enabled to create MHC map that was consistent with 
the IMGT/HLA reference map. However, as only two MHC haploid clone 
libraries (PGF and COX) were used, more studies are needed, before using the 
approach in HLA typing [99]. In the near future, the NGS typing of HLA genes 
may become a cost-effective method in the field of histocompatibility [100-
102].  
2.3.4 THE CONCEPT OF THE HLA ALLELE AND MHC HAPLOTYPE 
 
The HLA alleles differ in approximately 10-26 nucleotides from each other 
depending on the locus [103]. The peptide binding preferences for each HLA 
allele associate directly with the arrangement of the amino acid sequence that 
forms the peptide-binding site. Most of the polymorphism is observed in the 
region encoding the peptide-binding site (PBS), as shown in Fig. 7 (a part of 
HLA-DRB1 exon 2) [104].  
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Figure 7 The allele calling of HLA class II is typically analysed based on the nucleotide 
sequence of exon 2. A part of the coding sequence of HLA-DRB1 is presented here. 
Codons 9-14 are highly polymorphic and encode the peptide-binding site (part of 
pockets 4, 6 and 9). Identities with the consensus (HLA-DRB1*01:01:01) are 
indicated by dash. AA=amino acid. [Adapted from [78]IMGT/HLA Database 
(http://www.ebi.ac.uk/imgt/hla/)] [78]. 
Most of the HLA alleles are rare and have been reported less than three 
times. The rest of the HLA alleles have low-to-medium frequencies, with the 
exception of HLA-DPB1, where only a few alleles account for the majority of 
the genes. Typically, the majority of the different alleles of HLA-A, -B, -C, -
DRB1, and -DQB1 are evenly distributed between different populations. For 
example, in most populations, approximately 20 alleles within HLA-DRB1 
account for the > 90 % of all alleles found in the population [81,105]. Due to 
the LD block structure (where nearby genomic fragments are inherited 
together), some HLA alleles and haplotypes are found more frequently than 
expected in the population. In addition, it has also been shown that the same 
allele can be generated in two or more independent events (i.e., convergent 
evolution). [104] 
The term of MHC haplotype is used to describe the cis phase of the genes’ 
alleles on the same chromosome (Fig. 8 and 9). The haplotype structure 
between closely related MHC genes can be broken by gene conversion or 
recombination during meiosis. In recombination, chromosome homologs are 
wound tightly around one another, and genetic segments are exchanged (in a 
process called crossing over) [15]. Figure 9 shows how MHC genes are 
inherited as a haplotype block without any recombination as well as with the 
recombination. 
Exon 2                                   10                  15                  20                                  "
 DRB1*01:01:01       CA CGT TTC TTG TGG CAG CTT AAG TTT GAA TGT CAT TTC TTC AAT GGG ACG GAG CGG GTG"
 DRB1*03:01:01:01    -- --- --- --- GA- T-C TC- -C- -C- --G --- --- --- --- --- --- --- --- --- ---"
 DRB1*15:01:01:01    -- --- --- C-- --- --- -C- --- AGG --G --- --- --- --- --- --- --- --- --- ---"
 "
  
AA Pos.                                           10         20         30           "
 DRB1*01:01:01                            GDTRPRFLWQ LKFECHFFNG TERVRLLERC"
 DRB1*03:01:01:01                         --------EY STS------- -----Y-D-Y"
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Figure 8 A HLA-A, -B, -DRB1 and –DQB1 haplotype is shown with the traditional HLA alleles 
(haplotypes A*01-B*08-DRB1*03-DQB1*02 and A*03-B*35-DRB1*01-DQB1*05) and 
with using the extended MHC haplotype approach (haplotypes A*01-B*08-C4-
BTNL2-DRB1*03-DQB1*02 and A*03-B*35-C4-BTNL2-DRB1*01-DQB1*05). 
 
 
Figure 9 The inheritance of MHC haplotypes with (child 2) and without (Child 1 and 3) 
maternal recombination.  
Most commonly, the phase of the HLA genes (haplotype) is estimated 
probabilistically using LD. When alleles of different contiguous loci occur 
together more often than expected from a random distribution according to 
their individual frequencies, the neighbouring loci are said to be in LD. The 
LD blocks are characterized as genetic segments with low recombination 
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[106]. The strength of LD is traditionally expressed by r2 or D’. For multiallelic 
genes, one might argue that there are no good measures available, however, it 
has been suggested that, D’ estimates the strength of LD (>0.80, strong LD; 
0.8-0.5, moderate LD; 0.5-0, weak LD) better than r2 [107]. If a meiotic 
recombination occurs (Fig.9), the new haplotype is formed from a 
combination of the parent’s heterozygous haplotypes. Recombination 
hotspots have been described in the MHC region, denoting locations in the 
genome where the possibility of a meiotic recombination occurring is higher 
than the average. Known recombination hotspots occur in the MHC class I 
between HLA-A and –C and between HLA-B and MHC class II, and within 
class II (near HLA-DPB1). It is unlikely that recombination will occur between 
HLA-DRB1 and –DQB1. The location of recombination hotspots and the 
length of LD blocks are population-specific [50,108]. 
2.3.5 HLA POLYMORPHISM IN POPULATIONS 
The MHC allele and gene frequencies show strong differentiation between 
populations.  Individuals who are heterozygous in their MHC alleles have a 
wider peptide-binding repertoire and therefore have a higher likelihood to 
respond to a wider range of pathogens [109]. The extensive population 
variability of the MHC genes may be a consequence of their functional ability 
to respond to more pathogen variants (i.e., pathogen-driven selection), as the 
HLA molecules play a critical role in immunity. However, pathogen-driven 
selection is not well understood. In addition, selective pressures (negative 
frequency-dependent selection and fluctuating selection) or a recent 
admixture of populations may offer explanation for the diversity of HLA 
alleles. A recent study confirmed that the geographical distances can be used 
to predict the HLA genetic diversity [109]. It has also been suggested that 
HLA class I and class II molecules have district evolution mechanisms 
[110,111]. The analysis of the distribution of HLA alleles has shown evidence of 
convergent evolution events among the HLA alleles, suggesting that some 
alleles are found in distinctive haplotypes in different populations. Typically, 
HLA alleles are related by descent from a common ancestral sequence (e.g., 
HLA-DRB1*15:01 and *15:02), but in some cases the alleles have developed 
independently.  As an example, is HLA-DRB1*08:04 haplotypes have with 
district HLA-DQB1 and –DQA1 alleles and B*52:01:01 and B*52:01:02 alleles 
[109]. 
The polymorphism of the HLA alleles in different population has been 
used to study the genetic distances between populations [112]. The study of 
HLA diversity in outbred populations has illustrated, for example, only two 
ethnicity-specific haplotypes for Europeans (HLA-DRB1*08:01:01 and 
*16:01:01) and several population-specific alleles for Asians, Africans and 
Native Americans. In addition, some rare haplotypes are more common in 
inbred populations, such as the extended A*26:01-C*12:03-B*38:01-
DRB1*04:02-DQB1*03:02 haplotype, which has a frequency of over 10% in 
the Ashkenazi Jewish population [104]. Similarly, by studying different dog 
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breeds, a restricted diversity of DLA alleles (due to e.g., inbreeding) has been 
observed within each dog breed, as well as a similar diversity of haplotypes 
between different dog breeds [79,113].  
The studies have shown that HLA frequency data is highly correlated with 
geographic distances, illustrating a north-to-southwest axis. Extreme 
distributions of HLA diversity have been reported in subpopulations, such as 
the Norwegian Sami. The Norwegian Sami are genetically more closely related 
to the Finnish population than to other Norwegians. In addition, it has been 
found that the Finns themselves have a distinctive population substructure 
compared with other Europeans. The study of the LD patterns between MHC 
alleles in different populations provides a view to evolutionary relations 
between alleles and illustrates shared MHC blocks between alleles [104,109]. 
Collaborative studies including the International Histocompatibility 
Workshops and HLA-NET have examined the distribution of HLA alleles in 
different worldwide populations. Many of these populations’ HLA data are 
available in the AlleleFrequencies.net –database [114] 
(http://www.allelefrequencies.net) or the dbMHC database 
(http://www.ncbi.nlm.nih.gov/projects/mhc). In Fig. 10, the frequency of 
HLA-DRB1*15 from the former is shown [114].  
 
Figure 10 The HLA-DRB1*15:01 allele frequency in the world based on the distribution of HLA 
alleles imported from the AlleleFrequencies.net –database (adapted from 
http://www.allelefrequencies.net)[114] 
2.3.6 MHC AND TRANSPLANTATION 
The HLA genes play an important role in stem cell transplantation and self vs. 
nonself –recognition in organ transplantation [115]. HLA-matching between 
the donor and recipient is critical in hematopoietic stem cell transplantation 
(HSCT) and bone marrow transplantation (BMT) for a successful outcome. 
The major complication in HSCT is an occurrence of graft-versus-host disease. 
HLA$DRB1*15:01-
h/p://www.allelefrequencies.net/-
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Solid organ transplants are not as sensitive for HLA mismatching as the 
HSCT, but graft rejection and loss are associated with HLA mismatching or 
mismatches.  
The main objective is to find a donor with the same HLA-A, -B, -C, -DRB1, 
-DQB1 alleles. A 10/10 allelic match represents that all the alleles are identical 
with donor and recipient [116,117]. However, the variability of the HLA 
complex restricts the number of possible donors and the most ideal donor, an 
HLA-identical sibling, is not always available. The likelihood of finding a 
suitable unrelated donor depends on the patient’s racial and ethnic 
background [118]. Knowledge of the HLA diversity within each geographical 
region is used in finding a suitable donor. In national bone marrow (stem cell) 
registries and in the Bone Marrow Donor Worldwide (BMDW) databank 
(http://www.bmdw.org), millions of volunteer stem cell donors are registered. 
Due to the difficulties in finding an HLA-matching donor, many patients will 
be transplanted with a graft from an HLA-mismatched donor. Here, the 
challenge is to find the most optimal mismatched donor and to predict 
whether the recipient will being to make antibodies against the donor, as 
immunogenicity is not the same for every individual and certain mismatches 
are more permissible than others [119]. Previous studies have also suggested 
that MHC class III and HLA-DPB1 regions are especially important in HSCT 
and influence on the outcome of the transplantation [120-122]. 
2.3.7 MHC DISEASE ASSOCIATION STUDIES 
Previous GWASs have pointed out the importance of MHC in disease 
association studies (GWAS Integrator, http://genome.ucsc.edu, [123]). HLA 
has been confirmed as the major genetic factor for many autoimmune and 
inflammatory mediated diseases, including celiac disease (CD) [94,124-126], 
Graves’ disease (GD) [127-129], T1D [130-134], MS [44,135], rheumatoid 
arthritis (RA)  [136-140], ankylosing spondylitis (AS)  [141], systemic lupus 
erythematosus (SLE) [142,143] and narcolepsy [144] (Table 2). Autoimmune 
diseases, most often chronic and impossible to cure, affect up to 4% of the 
population in industrialized countries [56]. GWAS have revealed novel disease 
associations such as schizophrenia and Parkinson disease [145] and indicated 
additional susceptibility loci for autoimmune and inflammatory diseases 
outside MHC [50,86]. In addition, a growing number of the MHC associations 
with drug hypersensitivity reactions have been reported, including abacavir 
hypersensitivity syndrome (association with the abacavir and HLA-B*57:01) 
and the Steven-Johnson syndrome (association with carbamazepine and 
HLA-B*15:02) [146].  
Several autoimmune, infectious and inflammatory diseases share some 
common predisposing MHC loci, as well as disease-specific markers [147]. 
The different associations with different disease outcomes may be due to 
different antigens and the presentation of different disease-specific 
autoantigens [56]. A frequently shared disease susceptibility allele, HLA-
DRB1*04 (or haplotypes including the allele) has been associated with several 
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diseases (e.g., RA, T1D [130,136]). T1D and celiac disease share genetic 
susceptibility markers suggesting common genetic background in HLA for 
these two autoimmune diseases [148,149]. Furthermore, many autoimmune 
diseases (e.g., GD, SLE) have been associated with HLA-DRB1*03 or with the 
haplotype 8.1, typically referred as the autoimmunity haplotype [ancestral 
haplotype (AH) 8.1)], noticeably important in disease predisposition [150]. 
Table 2 describes the MHC associated diseases and conditions more 
thoroughly.  
Table 2. Disease associations of HLA alleles and their combinations 
HLA association Disease Reference 
HLA-A*29 Birdshot retinopathy [151] 
HLA-B*27 Ankylosing spondylitis (AS) [141,152,153]  
HLA-C*06 Psoriasis vulgaris [154] 
HLA-DRB1*01 Coronary artery disease (CAD) [155] 
HLA-DRB1*03 Addison's disease (AS) [156] 
  Chronic active hepatitis [157] 
  Graves Disease (GD) [152,158]  
  Type I Diabetes (T1D) [130] 
  Myasthenia gravis [159] 
  Sjögren's syndrome [160] 
  Systemic lupus erythematosus (SLE) [161] 
  Sarcoidosis [162]  
HLA-DRB1*04 / Rheumatoid arthritis (RA) [136] 
Shared epitope # Rheumatoid arthritis (RA) [137,138]  
HLA-DRB1*04 T1D [130] 
HLA-DRB1*08 Systemic lupus erythematosus (SLE) [143] 
HLA-DRB1*15 Multiple sclerosis (MS) [44,135] 
  Narcolepsy [144] 
  Sarcoidosis [163,164] 
HLA-DQB1*02, 
*03:02 
Celiac disease (CD) [124,125,165]  
# *Shared epitope 70-74 QKRAA/QRRAA/RRRAA (DRB1*01:01, *01:02, *04:01, *04:04, *04:05, 
*04:08, *10:01, *14:02) 
 
Furthermore, T1D has been shown to associate with peptide binding 
pocket nine (P9) of the DQB1 molecule, where β57 shows both susceptibility 
[alanine (Ala) or serine (Ser)] and protective associations [aspartic acid (Asp)] 
[46]. The β57 is a critical residue of the HLA-DQB1 involved in antigen 
presentation and TCR interaction [46,133,166]. In addition, RA has shown 
evidence of association with the shared epitope within the HLA-DRB1 peptide 
domain, at positions β70-β74 [138]. The association between antigen binding 
pockets’ residues and disease sheds light on the importance of the particular 
antigen binding to pocket and genetic susceptibility.  
The main trigger in autoimmune diseases is probably antigen presentation 
and T cell activation [167]. The immune response to a particular pathogen 
may depend on the MHC alleles carried by an individual. Many of the HLA-
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alleles that are associated with a disease are common in healthy members of 
the population, suggesting that other genes and/or environmental factors are 
needed for disease manifestation. In addition, it has been suggested that the 
HLA risk variants might confer an evolutionary advantage [168].  
The HLA associations with various diseases are typically much stronger 
than is typical for GWAS, showing high odd ratios (OR) for predisposing 
markers and low OR for protective markers. As an example, the HLA 
susceptibility haplotype for T1D has an OR of 3.64 (DRB1*03:01-
DQA1*05:01-DQB1*02:01) and the protective haplotype has an OR of 0.03 
(DRB1*15:01-DQA1*01:02-DQB1*06:02) [169]. However, while this makes 
them easy to detect in a GWAS, the mechanism behind HLA association is not 
well understood. It has been suggested that different dog breeds represent an 
excellent comparative model for human diseases. A good example is diabetes, 
which has a similar genetic susceptibility and predisposing markers in dog 
and human (MHC). Again, the similarity in MHC genes further suggests that 
results of investigating other genetic markers in dogs can have implications 
for humans as well [113].  
With the complex MHC structure and multifactorial etiology of the traits, 
the causal variant(s) responsible for the effect are challenging to resolve and 
underlying pathogenic mechanisms difficult to understand. Furthermore, up 
to 90% of AS patients are positive for HLA-B*27 [143], but only 5% of the 
individuals with the HLA risk allele will actually have the disease. Thus far at 
least twelve loci [i.e., endoplasmic reticulum aminopeptidase 1 (ERAP1)] and 
chromosomes 2p15 and 21q22 have shown evidence of association with AS in 
Europeans [143,152,153,170]. 
2.3.8 THE EXAMPLE OF CELIAC DISEASE 
One of the few well understood pathogenesis of HLA related diseases, is celiac 
disease, a chronic inflammatory disease, with an identified genetic component 
(DQ2 in cis or trans [(DQA1*05-DQB1*02 with HLA-DRB1*03:01) or DQ8 
(HLA- DQA1*03:01-DQB1*03:02 with HLA-DRB1*04)] and a known 
environmental trigger (here, glutein) (Fig. 11)[124-126]. Celiac disease is an 
autoimmune-mediated systemic disorder characterised by a permanent 
intolerance to wheat gluten, primarily affecting the gastrointestinal tract [171].  
In celiac disease, the MHC class II molecules present deamidated gluten 
particles to T cells in the small intestine, resulting in an abnormal CD4+ T-
cell-initiated immune response to gluten. In addition, evolutionary studies 
have indicated that an interaction between at least two genes of the HLA-
DRB1*03:01–DQ2 haplotype is needed for disease predisposition [124]. 
Indeed, these observations of celiac disease may assist to identify the 
pathogenic mechanisms in other autoimmune and inflammatory disease.  
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Figure 11 Most patients with celiac disease express a particular HLA-DQB1 heterodimer with 
HLA-DQA1*05 and HLA-DQB1*02 on the cell surface of APC, either encoded by 
genes that are carried in same chromosome (cis) or in different haplotype on 
different chromosome (trans) [124]. The MHC class II molecule presents gluten 
peptides that have been deamidated by tissue transglutaminase (TG2) to CD4+ T 
cells[124]. 
2.3.9 MHC (NON-HLA) DISEASE ASSOCIATION WITH DISEASE 
Several reports have associated various non-HLA gene polymorphisms, 
including TNF, lymphotoxin alfa (LTA), the human MHC class I chain-related 
gene A/B (MICA/MICB), BTNL2, C4 and the receptor for advanced glycation 
endproducts (AGER or RAGE) with autoimmune and inflammatory traits 
[134,142].  
Cytokine-coding genes, such as the tumor necrosis factor (TNF) produced 
by macrophages, and lymphotoxin alfa and beta (LTA and LTB) produced by 
lymphocytes, have key roles in the regulation of the inflammatory response 
and granulomatous inflammation [129,140,172]. The MHC region codes for 
three complement coding proteins; complement C2, C4 and complement 
factor B. The major function of the complement proteins is the activation of 
the complement pathway, which results in the formation of the membrane 
attack complex. Interestingly, the variation of the C4 gene numbers and the 
deficiency of C4 proteins (less than two copies of the gene) have both been 
associated with several autoimmune diseases [142]. The receptor for advanced 
glycation end products (RAGE or AGER) is a member of the immunoglobulin 
gene superfamily and BTNL2 is a member of the butyrophillin family, both 
encoded by the MHC class III region. RAGE regulates autophagy and 
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Furthermore, in sarcoidosis, RAGE is expressed in granulomas and subjects 
carrying the –374 T allele (rs1800624) have an increased RAGE expression 
[174]. BTNL2 acts as a co-stimulatory molecule in T-cell activation and 
evidence of disease association has been reported, e.g. with Grave’s disease 
and sarcoidosis [173,175].  
  
2.4 MHC CONTRIBUTES TO SARCOIDOSIS 
PREDISPOSITION 
2.4.1 CLINICAL CHARACTERISTICS OF SARCOIDOSIS 
Genetic factors play an essential role in immunodeficiency and the 
susceptibility to infectious and inflammatory diseases, including sarcoidosis 
(MIM: 181000). Sarcoidosis is a multi-organ immune-mediated disorder 
characterised by the presence of non-caseating epithelioid granulomas in 
affected organs [176]. Sarcoidosis, first recognized over 120 years ago, is a 
systemic disease of unknown aetiology and with a varying clinical course [4]. 
It is a complex disease, with interactive effects from the environment and 
multiple genes [177], and has heritability estimates (see chapter 2.1.1) as high 
as 66% [178] (i.e., significantly higher than in many autoimmune and 
inflammatory disorders). Previous studies suggest that sarcoidosis is 
recessively inherited disease with incomplete penetrance [179]. 
Sarcoidosis occurs throughout the world affecting all races but with 
differences in prevalence and incidence with respect to geographical locations 
[180]. Similar rates are observed in Northern Europe and the US. In Finland, 
on the basis of national study in 1984, the crude prevalence and annual 
incidence of sarcoidosis in 20 to 65-year-olds were estimated as 28.2 per 
100000 and 11.4 per 100000, respectively [5,6]. Among African Americans, 
sarcoidosis is three times more common than in European Americans. The 
lowest rates are probably observed in Japan, with an incidence of 1-2/105 
[5,6,181-183]. Sarcoidosis is uncommon among children and adolescents, and 
many studies have reported an increase of incidence during mid-adulthood 
[176,181]. The average mortality of sarcoidosis ranges from 1−6% 
[180,184,185]. 
The diagnosis of sarcoidosis is established when clinical and radiological 
observations (Fig. 12) are supported by histological evidence of noncaseating 
epithelioid cell granulomas (in a biopsy sample) and other diseases [e.g., 
tuberculosis, MS, Chronic beryllium disease (CBD] have been excluded [180]. 
In principle, all organs of the human body may be affected by sarcoidosis. 
Most often lesions are found in the lungs (90% of all patients) and bronchial 
walls, in lymph nodes, eyes, liver/spleen, skin, CNS, heart and the upper 
airways. Clinical manifestations depend on the location of the inflammation. 
Up to 50% of patients have extrapulmonary disease localisations (Fig. 13) 
[5,186-188]. A biopsy can be obtained from the lung parenchyma (a 
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transbronchial biopsy), a skin nodule or enlarged peripheral lymph node. The 
biopsy is difficult to obtain from patients with suspected neurosarcoidosis 
and/or cardiac disease, and these manifestations are typically under-
diagnosed [189]. Common clinical manifestations for sarcoidosis include chest 
pain, uveitis, nodules in the skin, erythema nodosum, arthralgia, dyspnea and 
cough. [4]. Sarcoidosis can also stimulate unusual overproduction of vitamin 
D3 (calcitriol) by activated macrophages and granulomatous tissue causing a 
complication referred as hypercalcemia. In sarcoidosis hypercalcemia often be 
accompanied by renal insufficiency [190]. 
 
 
Figure 12 Radiological staging of pulmonary sarcoidosis and overview of diagnostic 
procedures. In addition to a typical clinical picture consistent with sarcoidosis, a 
confirming tissue biopsy is also required with the presence of noncaseating 
granulomas (Modified from [4,187])  
Previous studies have indicated that sarcoidosis is not a single disease 
entity but a syndrome of heterogeneous diseases. The clinical picture and 
prognosis of sarcoidosis vary starting from spontaneous remission within 1-2 
years to chronic disease with functional insufficiency of many organs. Indeed, 
the majority of the sarcoidosis patients with pulmonary involvement alone 
have a favourable prognosis but approximately 20% develop a chronic, 
disabling disease. The reason, why in some patients sarcoidosis resolves and 
in some becomes chronic, is poorly understood [191]. The resolving 
pulmonary sarcoidosis is typically associated with bilateral hilar 
lymphadenopathy (BHL) and non-fibrotic pulmonary infiltrates. Löfgren 
syndrome, the acute form of sarcoidosis accompanied with erythema 
Five radiographic stages of pulmonary sarcoidosis, 
        
Stage 0 Normal chest X-ray   
Stage I Bilateral Hilar adenopathy (BHL) 
Stage II 
Bilateral hylar adenopathy and pulmonary 
infiltries 
Stage III Pulmonary infiltries without BHL 


















Five radiographic stages of pulmonary sarcoidosis!
 "  "  "  "
Stage 0" Normal chest X-ray"  "
Stage I" Bilateral hilar lymphadenopathy (BHL)"
Stage II"
Parenchymal shadows and bilateral hilar lymphadenopathy in 
chest"
Stage III" Parenchymal shadows alone"  "
Stage IV" Fibrotic changes"  "
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nodosum (EN) and acute arthritis and/or uveitis, is a genetically distinct 
subgroup of sarcoidosis with high frequency of HLA-DRB1*03 and has 
typically a favourable prognosis. Löfgren syndrome is common in 
Scandinavian patients, but uncommon in e.g., African-American and [192].  
In general, an asymptomatic patient with only lymphadenopathy and/or 
with only slightly abnormal lung function can be followed up without the need 
for therapy. In progressive disease, when damage of organ function is 
suspected or already present, corticosteroids are the first line of therapy. In 
addition, TNF-inhibitors have been shown to improve lung function and 
reduce extra-pulmonary manifestations [193,194]. New therapies for 
sarcoidosis warrant a better understanding of the pathogenesis of sarcoidosis 
and the immunological pathways linked to the disease. In the end-stage 
pulmonary and cardiac sarcoidosis, organ transplantation can be considered. 
However, granulomas can re-occur in transplanted organs [195]. 
 
 
Figure 13 The average estimations of the extra-pulmonary manifestations of sarcoidosis 
(reviewed in [187]). In Finland (n=571, sarcoidosis patients seen at Mjölbolsta 
Hospital, Finland during years 1955-1987)[5], the prevalence of extra-pulmonary 
locations (>1%) sarcoidosis were the following: skin (5%), peripheral 
lymphadenopathy (25 %), eye (7%), spleen (4%),  
EN (erythema nodosum) (13%).  
2.4.2 PATHOPHYSIOLOGY OF SARCOIDOSIS 
The most probable pathophysiology of sarcoidosis is the dysregulation of the 
innate immune response to unidentified inhaled or infectious antigens 
[196,197]. To date, no single causative environmental trigger has been 
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phenotypes have different environmental triggers including mold, 
mycobacterial or propionibacterial antigen (Mycobacterium tuberculosis, 
(Propionibacterium acnes, P. granulosum, respectively), inorganic particles, 
and insecticides [177,197-201].  
 
 
Figure 14 The development of nonceseating granulomas in sarcoidosis. Foreign antigen(s) are 
presented by antigen presenting cell (APC) to promote the release of cytokines 
(TNFα, IFNγ, IL-2) from monocytes and type 1 T helper cells (Th0). This causesthe 
T-effector cells (Th1) and monocytes to gather at the disease site. TCR=T cell 
receptor [202] 
The immune-pathogenic mechanism of sarcoidosis is complex (Fig. 14) [162]. 
Sarcoidosis is characterized by granulomas, comprising of epithelioid cells, 
fibroblasts that are encircled by mononuclear cells and lymphocytes (CD4+ Th 
cells, CD8+ T cells and B cells). Granulomatous disorders include a wide 
spectrum of common and rare disorders, including chronic granulomatous 
disease (CGD), tuberculosis and Crohn's disease [202]. The formation of a 
granuloma is dependent on the response to antigenic stimulation and 
presence of previously mentioned cells [203]. The aggregation of cells in 
granulomas is probably promoted by the immune response to the pathogen 
[158]. Based on immunohistochemical staining of granulomas, most of the 
affected lymphocytes are CD4+ T cells, but CD8+ T cells are also observed in 
the periphery of the granulomas [204,205]. In addition, tissues affected by 
sarcoidosis have unregulated expression of interferon (IFN)-γ, TNF, and 
interleukins (IL-2, IL-12, IL-18 and IL-27), which regulate the CD4+ T 
lymphocytes to differentiate and activate the macrophage response [191,206]. 
Patients with sarcoidosis also have an increased proportion of T cells in the 
bronchoalveolar lavage fluid [207]. Evidence of association between 
sarcoidosis and the decrease of T regulatory cells, the negative immunological 
feedback signals, and the natural killer cells highlight the importance of the 
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2.4.3 GENETIC FACTORS OF SARCOIDOSIS  
Epidemiological findings in family, population-specific and multi-ethnic 
studies suggest that sarcoidosis is partially a genetic disorder, and that genetic 
factors may determine the clinical course [178,182,210]. Both linkage and 
association studies, including the recent GWASs, have shown a strong role for 
MHC in susceptibility to sarcoidosis [7]. Associations with the particular MHC 
genes (e.g., HLA-DRB1) have repeatedly been encountered in various ethnic 
groups and disease severities. As a complex disease, effects from multiple 
genes and environmental factors are needed for disease predisposition. Many 
of thee effects are probably relatively small, except in the case of the HLA 
genes (with OR for predisposing genes ranging between 2 and 12 [211]), which 
have been characterized as the main contributor in disease susceptibility to 
sarcoidosis across different ethnic populations [212]. 
2.4.3.1 MHC and sarcoidosis 
The HLA genes are the most extensively studied susceptibility genes in 
sarcoidosis (Table 4) [164]. Both predisposing and protective HLA class I and 
class II associations have been found in different ethnic groups: some HLA 
risk loci are shared, whereas others are ethnicity-specific [211]. The current 
understanding of the pathophysiology of sarcoidosis suggests that HLA class 
II genes, mostly the HLA-DRB1 alleles, are likely to be involved in sarcoidosis 
susceptibility. However, some studies suggest that HLA class I and class II 
associations have independent effects from both loci [213]. Typically, alleles 
HLA-DRB1*03, *11, *12, *14 and *15 represent the risk factors and HLA-
DRB1*01 and *04 are protective ones.  In addition to allelic association, the 
peptide-binding sites of the HLA genes have been indicated to be critical in 
disease pathogenesis [214,215]. The published HLA associations with 
sarcoidosis are summarized in Table 3.  
Despite several clinical and genetic studies, there are no biomarkers that 
can estimate the prognosis or evaluate the treatment effects in sarcoidosis. 
The only exception is that HLA-DRB1*03 positive patients with Löfgren 
syndrome (LS) have a favourable prognosis compared with HLA-DRB1*03 
negative LS patients (95% vs. 49%, respectively) [192]. In a Swedish study, 
sarcoidosis patients with peptide-specific T cells and HLA-DRB1*03:01 had a 
favourable prognosis and the antigen-driven stimulation of the T cells was 
supported [216]. Before using HLA types as genetic markers for an association 
with a particular disease phenotype, a replication of the variant is needed in 
independent populations.  However, it should be noted that chronic beryllium 
disease (CBD), a sarcoidosis-like granulomatous disease, has strong HLA 
associations showing an increased prevalence of HLA-DPB1 alleles containing 
a glutamic acid at amino acid position 69 (Glu69) with  ORs over 10 [217,218]. 
Because of similar clinical pictures in sarcoidosis and CBD, it has been 
hypothesized that chronic sarcoidosis could have the same risk factor as 
Glu69 (typically HLA-DPB1*02:01) [219]. However, previous studies have 
shown conflicting results regarding sarcoidosis and HLA-DPB1 associations 
  37 
[220]. Future studies are needed to address the HLA-DPB1 interaction with 
other MHC genes in sarcoidosis, especially in the development of chronic 
sarcoidosis.  
 
Table 3. HLA associations with sarcoidosis and its various disease phenotypes 
HLA association Susceptibility/OR  Prognosis Subphenotype Reference 
HLA-A*03, -B*07 Risk factor Persistent   [213,221] 
HLA-A*01, -B*08 Risk factor Good 
prognosis 
Arthritis  [162,164,213,222]  
HLA-DRB1*01 0.1-0.5     [211,222-224] 
HLA-DRB1*03 
(HLA-DQB1*02:01) 
1.9 (all sarcoidosis) 
/ 6.7-12.5 (LS) 
Good 
prognosis 
Acute onset, LS  [162,211,224]  
HLA-DRB1*04 0.2-0.7 / 7.5    Ocular sarcoidosis, 
Heerfordt’s syndrome 
[211,225] 
HLA-DRB1*08:03 2.0   Ocular sarcoidosis, 
Japanese patients 
[226] 
HLA-DRB*11:01 1.5-2.0   Stage II/III chest X-ray [214,224] 
HLA-DRB1*12:01 2.1-14.7     [211,214] 





1.3-1.8 Persistent   [214,224,229] 
pocket 4 (DRAla71 in 
HLA-DRB1), pocket 9 
(DQPhe9 in HLA-
DQB1) 
2.2 and 2.4     [215] 
LS, Löfgren syndrome 
 
2.4.3.2 Non-HLA and sarcoidosis 
From the MHC class III region, most importantly, the variants in TNF and 
BTNL2 genes have shown evidence of association with particular disease 
phenotypes of sarcoidosis [175,230]. TNF is a key factor in granuloma 
formation and it is highly expressed in sarcoidosis patients. TNF has been 
shown to associate especially with progressive disease [231].  Indeed, the most 
promising non-HLA association with sarcoidosis is for a variant in the BTNL2 
gene (missense SNP rs2076530)[175]. It has been indicated that the non-
functional BTNL2 protein, which is structurally similar with CD80 and CD86 
molecules, acts as a negative costimulatory molecule [232]. In theory, BTNL2 
could increase T lymphocyte activation, which is compatible with the 
pathophysiology of sarcoidosis [175]. The rs2076530 association with 
sarcoidosis has been replicated in many populations (e,g., [230]), but 
contradictory findings exist as well, especially regarding the strong LD 
between BTNL2 and HLA class II alleles [233,234].  BTNL2 is also associated 
with numerous autoimmune and inflammatory diseases, including type 1 
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diabetes (T1D) and Crohn's disease [235,236]. In addition, also other SNPs in 
BTNL2 has been shown to associate with sarcoidosis e.g., rs9268480 [237].  
However, not many of the found non-HLA associations with sarcoidosis 
have been replicated in an independent sample: either the markers show 
contradictory results (e.g., [238,239]) or await replication (e.g., Rab23, CCR5 
and IL23R [240]). Again, the strong LD existing in the MHC makes it 
extremely complex to resolve which gene represents the primary association. 
The functionality of a particular variant is often not defined, as the strong LD 
within the MHC genes complicates finding the causal variant [212,241]. More 
extensive studies across MHC (including the non-HLA genes) are needed in 
order to describe the extended MHC haplotypes accurately. Using larger 
samples, genotyping multiple genes and using proper statistical approaches 
may assist us to identify the causal variants. 
2.4.3.3  GWAS and sarcoidosis 
A total of six GWASs have been carried out to investigate the genetic 
susceptibility to sarcoidosis. With traditional candidate gene case-control 
approaches, the studies have pointed out novel non-HLA candidate regions of 
interest (Tables 3 and 4). One of the most promising non-HLA markers is 
annexin A11 (ANXA11 on 10q22.3) [242] that encodes a molecule involved in 
various functions in calcium signalling, apoptosis and cellular proliferation. 
ANXA11 among HLA class II molecule, are detectable in human B-cell 
exosomes [243], which are involved in regulation the immune response 
[242,244]. The association of sarcoidosis with the non-synonymous SNP 
(rs1049550; P = 1.0 x 10 -12, OR=0.62) is significant across different 
populations. The association has been independently replicated in two 
European samples [237,245,246] and in a meta-analysis of both European 
Americans and African Americans [244]. Furthermore, the most recent GWAS 
[244] identified a novel SNP-SNP interaction between ANXA11 (rs1049550) 
and the HLA (rs9268839), which sheds light on the importance of the 
exosomes in sarcoidosis predisposition. Indeed, the suggested interaction 
between ANXA11 and HLA warrants replication studies, and it is tempting to 
speculate that in case of sarcoidosis, the dysregulation of the immune 
response (via HLA) may result in the dysfunction of ANXA11, that could in 
turn hamper apoptosis of activated inflammatory cells [244].  
In addition, previous GWASs in sarcoidosis have indicated other 
interesting non-HLA susceptibility loci at 6p21.32 (rs715299 in NOTCH4) 
[237], 10p12.2 (rs1398024 in C10orf67) [247], 11q13.1 (rs479777 in CCDC88B) 
[251], 12q13.3–q14.1 (rs1050045 in the 3’-UTR of OS9) [250]. However, in 
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Table 4. Non-HLA gene association with sarcoidosis. 
ACE, Angiotensin-converting enzyme; AGER, advanced glycation end product receptor; ANXA11, 
Annexin A11; BAG2, BCL2-associated athanogene 2; BTNL2, Butyrophilin-like 2 (MHC class II 
associated); CCDC88B, coiled-coil domain containing 88B; C6orf65, chromosome 6 open reading 
frame 65; C10orf67, chromosome 10 open reading frame 67;  OS9, osteosarcoma amplified 9; 
NOTCH4, Notch homolog protein 4 ; RAB23, RAB23, member RAS oncogene family; TNF, tumor 
necrosis factor; ZNF451,zinc finger protein 451; 
*rs2800629 associated with the good prognosis. 
 
2.4.3.4 The challenges in sarcoidosis genetic studies and future 
directions  
The challenging problem with complex genetic studies is to find the genes 
responsible for the trait or disease. As there is no well-established animal 
model for sarcoidosis, collaborative studies are needed to obtain sufficiently 
large samples sizes. Screening of the possible candidate region is typically 
done via genome-wide studies (e.g. GWAS), using samples from families, sib-
pairs, or case-control collections (unrelated affected individuals and unrelated 
unaffected individuals). As sarcoidosis is a rare disease, the collection of large 
families for linkage studies or affected subjects for GWAS is not cost-effective. 
Thus, to date, many of the published genetic sarcoidosis studies are traditional 
candidate gene approaches that do not detect novel susceptibility loci. In 
addition, it has been shown that especially the GWASs are strongly influenced 
by the selected study population, and the population stratification remains a 
challenge in genetic studies of sarcoidosis [142,233,237]. The impact of new 
research advances (e.g., NGS) with sarcoidosis remains rather modest so far. 
To overcome the strong LD in MHC and to detect independent susceptibility 
variants, more improved analytical methods (e.g., using extended haplotyping 
or RNA-based studies) and larger samples sizes with well-established diseases 
phenotypes are needed. 
 
Variant Position Yes P value/ OR Reference  
AGER (rs1800624) 6p21   0.004/ 2.8 [174] 
ANXA11 (rs1049550) 10q22.3 Yes 1 x 10-12 / 0.62 [242,244] 
BTNL2 (rs2076530) 6p21    1.1 x10-8/1.6-2.75 [175] 
C10ORF67 (rs1398024) 10p12.2 Yes 4.24 x 10-6 / 0.81 [247] 
NOTCH4 (rs715299) 6p21.3 Yes 6.51 x 10-10 (meta-analysis) [237,248] 
TNF (e.g. rs1800629) 6p21.3   >0.001/ 0.43 * [172,216] 
BAG2, C6orf65, KIAA1586, 
ZNF451 and RAB23 
(rs10484410) 
6p12 Yes  2.64 x 10-4/ 1.72 [249] 
OS9(rs1050045) 12q13.
3–q14.1 
Yes  9.22 x 10-8/ 1.24 [250] 
CCDC88B (rs479777) 11q13.1 Yes  2.68 x 10-18/ 1.18 [240] 
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3 AIMS OF THE STUDY  
The overall objectives of this study were to investigate the polymorphic profile of the 
MHC region in Finnish subjects and to address practical issues that should be taken 
into account in studying MHC disease association. In addition, the study aimed to 
investigate the MHC as susceptibility loci for sarcoidosis, a complex immune-
mediated disease.  The purpose of these activities was to find gene variants that 
predispose patients to sarcoidosis and predict the prognosis of sarcoidosis. If a 
significant correlation between the course of sarcoidosis and a genetic marker is 
found (i.e., disease phenotype associated marker), this may have clinical benefits in 
the treatment and the follow-up of the sarcoidosis patients. 
 
Our specific aims were: 
 
• To characterize the MHC profile among Finnish study subjects using 
extended MHC haplotypes covering the MHC class I, II and III region 
o To estimate the possible implications of the extended MHC haplotype 
to the study of the MHC related diseases (I) 
o To present practical guidelines and highlight challenges in MHC 
association studies (I) 
• To evaluate several different levels of the MHC association with sarcoidosis 
and its prognosis  
o To estimate whether the extended MHC haplotypes are advantageous 
in disease association studies in order to overcome the strong LD in 
the MHC (II, III, IV) 
o To estimate whether the previously identified MHC markers are 
associated with the Finnish sarcoidosis patients (II, III) 
o To detect novel MHC susceptibility variants for sarcoidosis 
phenotypes that are shared among Dutch, Czech, Swedish and Finnish 
sarcoidosis subjects (IV) 
o To pinpoint MHC disease variants associated with the disease course 
of sarcoidosis in order to distinguish the disease phenotype with 
genetic marker(s) (II, III, IV) 
 
  41 
4 MATERIALS AND METHODS 
4.1 STUDY COHORTS 
4.1.1 FINNISH POPULATION SAMPLE (VITA) (I, II, III, IV)  
The “VITA” population sample consisted of 150 consecutive voluntary subjects 
coming to Vita Laboratory Ltd, Helsinki, Finland for a health survey before 
accepting a new occupational post [252]. Because of the recruitment setting, 
subjects were unlikely to be related. Briefly, the mean age of the subjects was 
33.7 years (range 18-60), and 67% were females. A more detailed description 
of the sample is presented in Seppänen et al., [252]. The sample was used in 
our sarcoidosis study as a control group representing a healthy Finnish 
sample. However, we cannot reject the possibility that subjects who have later 
developed sarcoidosis are included in this sample. This study was approved by 
the Ethics Committee of Department of Medicine, Hospital District of 
Helsinki and Uusimaa, Helsinki, Finland (approval Dnro 6/E5/2001, 
25.1.2001). All study subjects provided a written informed consent.  
4.1.2 FINNISH SARCOIDOSIS SAMPLES (II, III) 
A total of 188 Finnish sarcoidosis patients with pulmonary sarcoidosis and 
150 control subjects were included in studies II and III (Table 6). The 
sarcoidosis patients were recruited from 17 pulmonary units in Finland. In all 
cases the diagnosis was based on the clinical presentation and was supported 
by a positive tissue biopsy and/or laboratory tests. Fifty percent of the patients 
had previously participated in a controlled clinical trial with a 5-year follow-
up [253]. In this study, patients with a clinical presentation likely to have a 
favourable clinical course, i.e. patients with LS, and patients requiring 
immediate treatment, were purposely excluded. As these patients would have 
been underrepresented in the current study, the sample set was expanded 
with additional patients having an acute onset sarcoidosis and patients with 
chronic sarcoidosis. The sarcoidosis patients underwent the following tests: 
chest radiograph, lung function tests (spirometry, diffusion capacity), 
electrocardiography (ECG) and blood samples [blood picture, liver enzymes 
tests, serum calcium and creatinine, serum lysozyme, serum angiotensin-
converting enzyme (S-ACE)]. All patients had pulmonary sarcoidosis and 59 
had one or more extra-pulmonary lesions. All the patients had a robust 
diagnosis of sarcoidosis and had a follow-up of at least 5 years. The Finnish 
Ministry of Social Affairs and Health approved the request to study hospital 
records of the patients (approval Dnro 362/E5/05). All study subjects 
provided a written informed consent.  
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4.1.3 THE SARCOIDOSIS COLLABORATION STUDY -SAMPLES (IV) 
Collaboration with three European Sarcoidosis Research groups increased 
the sample size in Study IV (Table 5) [224,254-256]. All the patients had 
pulmonary sarcoidosis. The Swedish sample consisted of 219 sarcoidosis 
patients and 360 healthy controls. The Swedish study was approved by the 
Ethics Committee of Karolinska Institute forskningsetikkommitté Nord (Dnr 
02-438: Dnr 2007/340-32), Stockholm, Sweden. The Czech sample consisted 
of 218 sarcoidosis patients and 180 healthy controls, and this study was 
approved by the Ethics Committee of Faculty Medicine of Palacky University 
and Faculty Hospital Olomouc (IGAMZCR NT/11117), Olomouc, Czech 
Republic. The Dutch sample consisted of 180 sarcoidosis patients and 180 
healthy controls. The study was approved by the Ethics Committee of the St. 
Antonius Hospital, Nieuwegein, The Netherlands. All participants gave a 
written informed consent.  
Table 5. Patients and controls included in the study  
    Sarcoidosis Controls 
    Before QC After QC Before QC After QC 
Discovery Sample     
  Finland 188 187 150 150# 
Replication Sample    
  Sweden 219 190 360 358 
  Dutch 180 180 180 173 
  Czech 218 208 180 178## 
Total 805 765 870 859 
QC=quality control, detailed in methods chapter 4.3; Plink software [257] 
#149 controls used in the C4 studies 
## 179 controls used in the haplotype analysis 
4.1.4 SARCOIDOSIS PHENOTYPES 
Patients were further divided into those with a disease resolved within 2-4 
years and those with persisting activity at that time point [163]. The activity of 
the disease was based on chest radiographic findings, lung function tests and 
laboratory values (S-ACE activity and lysozyme concentrations). The 
characteristics of the Finnish, Swedish, Dutch and Czech sarcoidosis patients 
are described in detail in Table 6.  
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Table 6. Patients were subgrouped according to LS and the disease activity. 
NL, Non-Löfgren; LS, Löfgren; NLR, non-Löfgren syndrome and resolved disease; NLP, non 
Löfgren and persistent disease 
4.2 GENOTYPING METHODS 
4.2.1 DNA EXTRACTION 
The DNA of the Finnish samples was extracted from the buffy coat fraction of 
whole blood by using NucleoSpin ® QuickPure columns (Macherey-Nagel, 
GmbH & Co. KG, Düren, Germany) or Gentra Puregene Kit (Qiagen, Vienna 
Austria; according to the Manufacturer’s protocol.  
4.2.2 HLA TYPING (I, II, III, IV) 
HLA genotyping was performed and/or analysed in an EFI (European 
Federation for Immunogenetics) accredited HLA Laboratory at the Haartman 
Institute, part of the University of Helsinki, Finland. Commercial HLA kits 
were used primarily (except HLA-DQB1 typings), and the reactions were 
performed according to the Manufacturers’ instructions and using the HLA 
nomenclature, release 3.5.0 (IMGT/HLA database). In principal, alleles that 
were identical in exons 2 and 3 (MHC class I) or exon 2 (MHC class II) were 
not resolved; expressed alleles in this category share the amino acid sequence 
of their antigen binding grooves. Other ambiguities were resolved with high 
resolution SSPs or sequencings HARPs. Two different people carefully 
interpreted all the HLA genotypes. The pipeline used for the HLA typing is 
presented in Fig. 15. 
    NL LS NLR NLP NL, no subgroup 
info available 
Discovery Sample         
  Finland 168 19 79 89 - 
Replication Sample         
  Sweden 112 78 33 75 4 
  Dutch 180 0 90 90 - 
  Czech 169 39 47 83 39 
Total  629 136 249 337 43 
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Figure 15 Pipeline for HLA genotyping with SSP or SBT using MHC class II gene, HLA-DPB1 
as an example 
SSPs (Olerup SSP AB, Stockholm, Sweden) were used for genotyping of the 
HLA-A and -B genes (Study I). PCR reactions from agarose-gel were evaluated 
manually and the alleles were called with SCORE software. SBT (InvitrogenTM, 
Life Technologies, Carlsbad, CA, USA) was used for detecting HLA-DRB1 
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identified with ABI Prism 3100 capillary electrophoresis (PE Applied 
Biosystems, Foster City, CA) and sequence interpretation was performed 
using the Assign-SBT v3.5+ software (Conexio Genomics, Applecross, 
Australia) and evaluated manually. The genotyping of HLA-DQB1 (Study I) 
was performed with a panel of lanthanide-labelled oligonucleotide probes, as 
described previously. For genotyping the HLA-DPB1 gene (Study I and III), 
both SSP and SBT were utilized, and the reactions performed and alleles 
called as previously presented (Fig. 14). As a quality control procedure, the 
HLA-DRB1 and HLA-DQB1 alleles were matched with the known LD pattern. 
For Study IV, we received HLA-DRB1 low-resolution genotypes for Swedish 
sample (NL+L n=184, controls n=187) and Czech Sample (NL+L n=90, 
controls n=179). 
4.2.3 C4 COPY NUMBER VARIATION AND C4 ALLOTYPING (I, II) 
The complement C4A and C4B gene copy numbers and a 2-bp silencing 
insertion at exon 29 (C4A CTins) in the C4A gene were analysed by 
quantitative genomic realtime-PCR (qPCR or RT-PCR) Rotor-Gene 3000 or 
6000 (Corbett Research, Sydney, Australia) using SYBR® Green labeling 
(ABsolute™ qPCR SYBR® Green Mix, AB-1159, Bgene, Epsom, UK) and 
Brilliant SYBR® Green QPRC Master Mix (Staratagene, AHDiagnostics, 
Skärholmen, Sweden). Data was analysed with the Rotor Gene software v 6.0 
(Qiagen) according to the Manufacturer’s instructions and using the 
amplification of a housekeeping gene (beta-actin) to assess the sample’s 
concentration. Detailed information on the qPCR protocols and primer 
sequences of C4, C4B and for C4 CTins is given in Paakkanen et al [258]. The 
allotypes of C4 were resolved from serum samples by immunofixation 
[Carboxypeptidase B (Roche Diagnostics Gmbh, Mannheim, Germany) and 
neuraminidase (Type IV Sigma- Aldrich Chemie Gmbh, Steinheim, Germany), 
polyclonal anti-C4 antibody (DiaSorin Inc., Stillwater, MN)] and the samples 
were separated by electrophoresis as described previously. The C4 CNV 
genotyping and allotyping were performed at the Transplantation Laboratory 
of the Haartman Institute.  
4.2.4 SEQUENOM® GENOTYPING (I, III, IV)  
Using a functional candidate gene approach, polymorphism of the selected 
genes from the MHC region, AGER (Study IV), LTA (Study I and IV), TNF 
(Study I and IV), BTNL2 (Study I, III and IV) and HLA-DRA (Study I and IV), 
were genotyped with SNPs. All the selected genes were covered entirely 
including the 5’ and 3’- flanking regions. The SNPs were selected from two 
publicly available databased, the HapMap database 
(http://hapmap.ncbi.nlm.nih.gov) and the dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP). In the SNP selection, the 
validation status, tagging quality, minor allele frequency (>0.01) and gene 
structure were used to evaluate the SNPs.  
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SNP genotyping was performed based on the differences of the single base 
extension (SBE) products using the Sequenom MassArray iPLEX system with 
9-10 ng of DNA as a template (Sequenom®, San Diego, CA, USA) with default 
settings. The multiplex PCR assays were designed with the AssayDesigner 
(Sequenom®, San Diego, CA, USA). The SNP alleles were called with 
MassARRAY® Analyzer and evaluated visually. We applied the following 
quality control filters: Assays (or samples) with a minimum total per-sample 
call rate of 90 %, SNP minor allele frequency (MAF) > 0.01, and Hardy-
Weinberg equilibrium (HWE) > 0.001 or water contamination were excluded. 
The average success rate of the assays was 99 %. No discrepancies were 
observed. The SNP genotyping was performed at the Institute for Molecular 
Medicine Finland (FIMM) Technology Centre, Helsinki, Finland.  
4.3 STATISTICAL METHODS 
We followed the STREIS principles to immunogenomic data analysis [259]. In 
general, the statistical analyses were performed with PAWStatistics version 18 
(PAWS, Inc., Chicago, IL, USA) if not otherwise stated. Allele, phenotype, 
haplotype, and amino acid frequencies were obtained by direct counting. The 
phenotype (positivity or a carrier) of a specific variant was considered when 
the subject had one or two copies of the variant. The phenotype describes the 
prevalence of the marker in a given sample/population (f =positivity of the 
variant/number of individuals in the sample). Each locus was tested for HWE 
using different software packages depending on the nature of the studied loci: 
ARLEQUIN 3.11[260], GENEPOP 4.1.4 [261] or Haploview [262] (biallelic 
SNPs only) was used to carry out Hardy-Weinberg testing. Marker 
distributions were statistically analysed with a Chi-square test (χ2) (or Fisher’s 
exact test when appropriate), as well as with logistic regression (a stepwise 
forward logistic regression). In the stepwise logistic regression, variants were 
removed until only significant variants were left. If only SNPs were studied, 
the software package PLINK [257] was used for the χ2 analysis. A two-sided p-
value less than 0.05 was considered statistically significant and ORs with 95% 
confidence intervals (CIs) were calculated as association measures. The results 
are shown as uncorrected p-values if not otherwise stated. When the values 
were corrected (Pc) for multiple comparisons, the Bonferroni method was 
used (Study II). 
Multi-locus and multi-allele haplotype frequencies were estimated from 
allele data using the Bayesian method with PHASE v. 2.1.1 [263]. Missing 
values were excluded from the analyses. SNP haplotypes were constructed 
using Haploview [262]. Considering the small sample size, in order to exclude 
unreliable haplotypes, only haplotypes greater than 1% (observed more than 3 
times) were used in the analyses. In Study III, the alleles with a too low 
observed frequency were lumped together [264,265]. To study the similarity 
of SNP haplotypes based on the genetic distance, the R-package ‘ape’ was used 
to create phylogenetic trees with Neighbour-joining algorithm according to 
  47 
the method of Saitou and Nei [266]. LD between alleles of each pair of loci 
was tested. The strength of LD was quantified by LD measures (D’ and r2) and 
determined using either the Haploview software [262] (for biallelic markers) 
or the ARLEQUIN 3.11 software [260] (for multiallelic markers). Due to the 
strong LD within MHC, a logistic regression was performed to study the effect 
of each marker in relation to the other risk alleles, and to adjust the markers 
for particular covariates, e.g., sex. For HLA-DRB1 and -DPB1 genes, amino 
acid (aa) residues in polymorphic hypervariable regions (HVR) were derived 
from nucleotide sequence of exon 2 using [267] SKDM HLA tool (Study II, III, 
unpublished data). Software package PHASE [263] was used for estimating 
recombination rates between the selected MHC loci (Study IV). For 
illustrating the overall recombination hotspot in the MHC region the HapMap 
data was used. 
In the Sarcoidosis collaboration study (Study IV), replication and meta-
analysis of selected SNPs was performed from the Swedish, Dutch and Czech 
samples. Results from primary χ2 association analysis (using the discovery 
and replications sample sets) were combined for the meta-analysis using a 
random effects model (PLINK software) [257]. The I2 measure was used to 
evaluate heterogeneity of the results between studies. The possible effect of 
population stratification on the results was studied more in detail using the 
Cochran-Mantel-Haenszel test [PLINK software] [257].
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5 RESULTS  
5.1 THE MHC PROFILE OF THE FINNISH SAMPLE (I) 
MHC alleles and haplotypes have differential distributions in different 
populations [2,108]. These distributions can be used to study genetic 
similarities between populations, and infer population history and 
evolutionary aspects. To explore the MHC profile of our population-based 
Finnish samples (n=150), we genotyped HLA class I (HLA-A, -B), class II 
(HLA-DRA, -DRB1, -DQB1, -DPB1), and a selected group of class III genes 
related to immunological pathways. We estimated the multi-locus extended 
haplotypes (see Fig. 8) and pairwise LD between loci to identify the most 
common MHC haplotypes and the LD patterns between tested variants.  
5.1.1 HLA ALLELE DISTRIBUTIONS  
The distribution of HLA alleles and phenotypes (i.e., carrier status for a 
particular allele) for the HLA-A, -B, -DRB1, -DQB1 and -DPB1 genes are 
shown in Fig. 16. No deviations from expected HWE proportions were 
observed. The allelic diversity was high at each HLA locus, with 15 HLA-A 
alleles, 21 HLA-B alleles, 26 HLA-DRB1 alleles, 11 HLA-DQB1 alleles and 19 
HLA-DPB1 alleles measured. HLA-A, -B and –DQB1 alleles were detected at 
low-resolution level, explaining the lower amount of alleles compared with 
the high-resolution typed ones. Two HLA-A alleles (*02 and *03) and four 
HLA-B alleles (*15, *07, *35, *08) were observed at frequencies greater than 
10%, and represented 66% and 50% of the allelic diversity observed at this 
locus, respectively. In MHC class II, four HLA-DRB1 (*15:01, *01:01, *08:01 
and *03:01), five HLA-DQB1 (*06:02, *05:01, *02, *03:01, *04) and four 
HLA-DPB1 alleles (*04:01, *04:02, *02:01, *03:01) were observed with 
frequencies above 0.1, and represented 43%, 72% and 85% of the HLA class 
II diversity in Finnish population, respectively.  





































  50 
 
Figure 16 Traditional HLA genes and their HLA allele and phenotype (i.e., the carrier status 
for an allele) frequencies (%) in the Finnish sample (n=150) (I) 
5.1.2 THE COMMON FINNISH HLA HAPLOTYPES 
Several extended haplotypes with different gene combinations (two-locus, 
three-locus and five-locus) were analysed in the Finnish sample. The four 
most frequent Finnish A~B~DR –haplotypes were A*03-B*35-DRB1*01:01 (7.1 
%), A*01-B*08-DRB1*03:01 (4.0%), A*02-B*07, DRB1*15:01 (3.5 %) and 
A*2-B*27-DRB1*08:01 (2.7 %). The most common Finnish A~B~DR –
haplotype is uncommon elsewhere in Europe, except among Swedish Sami and 
in Russia (Fig. 17) [114,268-271]. 
The MHC class II haplotype analysis including HLA-DRB1, -DQB1 and –
DPB1 alleles, indicated that while the DR-DQ block was constant (in strong 
LD), it showed polymorphism within the HLA-DPB1 gene (Fig. 18). In 
addition, the four most common HLA-DRB1 alleles, HLA-DRB1*01:01, 
*15:01, *08:01 and *03:01 all existed with at least three different HLA-DPB1 
alleles (HLA-DPB1*02:01, *04:01 and *04:02; HLA-DPB1*04:01, *04:02 
and *05:01; HLA-DPB1*03:01, *04:01 and *04:02; HLA-DPB1*01:01, 
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Figure 17 Haplotype A~B~DR frequencies in Finland, among Swedish Sami, in Russia and 
Ireland show distinct population differences on the haplotype frequency (I).  
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5.1.3 PAIRWISE LD BETWEEN HLA GENES  
High LD between loci and population-specific recombination hotspots 
characterize the MHC region [272]. The association between the Finnish 
HLA loci was estimated with the global LD (unpublished results; Table 7) 
showing that the HLA alleles were in strong LD with one another; the only 
exceptions were HLA-A with HLA-DRB1 and -DPB1 and HLA-DRB1 with -
DPB1, neither of whichreached the significance level (p<0.05). Analysis of 
the HLA class II haplotypes and LD patterns show that, as expected, the 
linkage of HLA-DRB1 to HLA-DQB1 was stronger than to HLA-DPB1. This 
indicates that in relation to HLA-DRB1, several different HLA-DPB1 alleles 
are found in the extended haplotypes, as shown in Fig. 18. As HLA-DRB1 and 
-DQB1 and HLA-B and -C, transmit together in northern Europeans [50], we 
used the HLA-DQB1 typing results as a quality control to verify the accuracy 
of the HLA-DRB1 allele callings, and to reduce the cost of genotyping; the 
HLA-C alleles were not detected in this study. 
The existence of a recombination hotspot can justify the lack of LD 
between loci [2,272-274]: HLA-A gene lies physically far away from class II 
and a recombination spot is known to exist in the MHC class II region 
between HLA-DRB1/DQB1 and HLA-DPB1 [112,264]. Given that, only two 
extended and conserved A~B~DRB1 haplotypes were observed; one with 
HLA-DRB1*03:01 and another with HLA-DRB1*13:02 [1,275]. A*01-B*08-
DRB1*03 haplotype is typically referred as the ancestral haplotype AH 8.1, or 
the autoimmune haplotype [1].  
 
Table 7. Significant (+) or non-significant (-) linkage disequilibrium (LD: r2) 
 between HLA genes 
HLA 
Locus 
A B DRB1 DQB1 
A   + - + 
B +   + + 
DRB1 - +   + 
DQB1 + + +   
DPB1 - + - + 
(Significance level=0.05) (Unpublished data) 
5.1.4 THE EXTENDED MHC HAPLOTYPE ANALYSIS 
Various SNPs within the MHC class III region have been described and 
implicated in disease association studies, as well as graft versus host disease, 
and variants in genes TNF, C4, BTNL2 and HLA-DRA have been associated 
with disease predisposition [59,120,122]. However, only few studies have 
described the phase of different non-HLA variants together with the 
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traditional HLA alleles [91,276]. Here, we combined the SNPs and gene copy 
number data in MHC with those in the traditional HLA genes, assessed the 
extended MHC haplotypes, and finally investigated the LD and shared 
fragments between loci in relation to the polymorphic HLA-DRB1. 
Fourteen of 74 genotyped SNPs were excluded due to low minor allele 
frequency (<0.01) or HWE p-value (<0.001). After quality control (QC), a 
total of 60 SNPs were accepted. Using a tag-SNP approach, we excluded 
additional five SNPs that were in total LD (r2=1) with another genotyped 
SNP. The strong LD pattern indicates a high likelihood that there are other 
SNPs (not genotyped here) in strong LD with our genotyped SNPs. The 
marker haplotypes were constructed combining the SNPs of TNF-LTA (TNF 
block), BTNL2 and HLA-DRA (BTNL2 block) and merging with the C4A and 
C4B gene copy numbers (C4 block). The rare TNF, C4 and BTNL2 haplotypes 
observed less than three times were excluded from the analysis. Taken 
together, five haplotypes covered 96% of TNF haplotypes, four haplotypes 
covered 99% of C4 haplotypes, and a further four haplotypes covered 80% of 
BTNL2 haplotypes. Our results corroborated the previous publications 
anticipating that the number of frequent TNF and BTNL2 haplotypes is 
limited, although the actual number of SNPs in the TNF and BTNL2 region is 
high [276].  
 
Table 8. The strong and significant pairwise LD (D’/r2)# between HLA-DRB1 alleles 
(observed n > 3) and MHC variants (traditional HLA alleles or TNF, C4 and BTNL2 blocks) (I) 
 TNF block C4 block BTNL2 block HLA-DQB1 HLA-DPB1 











DRB1*04:01 - - 1.0/0.4 (BTNL2_3) - - 
DRB1*08:01 - - 1.0/0.8 (BTNL2_4) 1.0/1.0 
(DQB1*04) 
- 
DRB1*09:01 - - - 1.0/0.8 
(DQB1*03:03) 
- 
DRB1*11:01 - - 0.9/0.8 (BTNL2_8) - - 
DRB1*12:01 - - 1.0/0.5 (BTNL2_10 
and _11) 
- - 







1.0/0.9 (BTNL2_7) 1.0/1.0 
(DQB1*06:04) 
- 
DRB1*15:01 - - 1.0/1.0 (BTNL2_2) 1.0/1.0 
(DQB1*06:02) 
- 
# Here the overall pairwise LD between loci is considered strong when D’> 0.8 (i.e., strong LD) and 
r2 > 0.4 (moderate LD), together with a P value < 0.05.  
 
The evaluation of the extended haplotypes containing TNF, C4 and 
BTNL2 blocks and HLA-DRB1 suggested that the strongest pairwise LD 
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exists between HLA-DRB1 and the BTNL2 block (Table 9). Corresponding 
with the HLA haplotypes, only HLA-DRB1*03:01 and HLA-DRB1*13:02 
formed conversed and extended MHC haplotypes covering also the TNF 
block (D’=0.8; D’=0.9, respectively) [1,50]. The LD and extended MHC 
haplotype analysis indicated that, in relation to HLA-DRB1, the highest 
degree of polymorphisms was observed in the MHC class I, TNF and C4 
blocks (Table 8) and in the HLA-DPB1 locus.  
We observed that in a number of cases, the same variant (SNP or CNV) 
was present in many different extended HLA-DRB1 haplotypes. This 
information can be used to further subgroup the HLA-DRB1 alleles according 
to the presence of a common variant, e.g., in the promoter region of LTA or 
TNF or a splice-variant (e.g., A allele in rs2076530; Table 9). Furthermore, 
the C4 deficiencies, previously associated with several inflammatory diseases 
[142,155,277-279], were observed within distinct extended HLA-DRB1 
haplotypes, C4A (C4_4) mainly with HLA-DRB1*03:01, and C4B (C4_2 and 
_3) with HLA-DRB1*01:01, *04:01, *08:01 and *13:01. Taking a closer look 
at the TNF and BTNL2 blocks, many of the SNPs or a SNP in strong LD (not 
genotyped here; http://www.snp-nexus.org) have been associated with several 
traits [280,281]. Furthermore, HLA-DRB1*11:01 and a rare HLA-
DRB1*15:01, both associated with inflammatory diseases, [214,282] shared 
same TNF haplotype (TNF_5).  
 
Table 9. A splice-site variant rs2076530 (A allele) in BTNL2 is present in different BTNL2 
blocks and forms two-locus haplotypes (>1% presented here) with distinct HLA-DRB1 alleles  
BTNL2 SNP 
rs2076530  
(A or G) 
in different BTNL2 
block 
HLA-DRB1 allele  
(observed n >3) 
Frequency of the DRB1-
BTNL2 haplotype 
  G  BTNL2_1 *01:01 0.147 
  G BTNL2_3 *04, *07 0.121 
  G BTNL2_6 *13:01 0.053 
A   BTNL2_2 *15:01 0.143 
A   BTNL2_4 *08:01 0.103 
A   BTNL2_5 *03:01 0.097 
A   BTNL2_7 *13:02 0.040 
A   BTNL2_8 *11:01 0.037 
A   BTNL2_10 *12:01 0.020 
A   BTNL2_11 *12:01 0.016 
A   BTNL2_12 *07:01 0.013 
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5.2 MULTIPLE LEVELS OF MHC ASSOCIATION WITH 
SARCOIDOSIS  
Previous linkage analyses and GWASs had shown a strong connection 
between MHC and sarcoidosis (Table 3 and 4). To further investigate the 
susceptibility loci, we performed a functional candidate gene analysis, 
focusing on MHC markers to discover variants that may contribute to the 
development of sarcoidosis and associate with the prognosis of sarcoidosis. 
We set out to replicate the known MHC associations with Finnish sarcoidosis 
patients and to locate novel susceptibility variants. To overcome the issue of 
sample heterogeneity, we subgrouped the sarcoidosis patients according to 
the progression of disease and Löfgren syndrome.  
5.2.1 VARIANTS IN MHC CLASS II ASSOCIATE WITH SARCOIDOSIS 
(II, III) 
Genes that encode the MHC class II molecules and are expressed on the 
surface of APC have been associated with sarcoidosis or its disease course 
(Table 3). We set out to confirm the association between HLA-DRB1 and 
sarcoidosis in the Finnish sample, with the secondary aim of investigating 
the association between HLA-DPB1 and sarcoidosis in general.  
Exon 2, which encodes the peptide-binding region of HLA-DRB1 and –
DPB1 was either sequenced or alleles were detected with the SSP method in 
188 cases and 150 controls. All the genotypes and ambiguities were checked. 
We showed that variants of HLA-DRB1 and –DPB1 associated with 
sarcoidosis or its disease course (Table 10). We replicated the previously 
reported HLA-DRB1*03:01 association with a favourable prognosis of 
sarcoidosis [224], showing that 34% of the patients with resolved disease had 
at least one copy of the allele, compared with 16% in the patients with 
persistent disease (P=0.007, OR=2.70, 95% CI=1.35–5.37). In addition, the 
extended MHC haplotype analysis presented a novel predisposing haplotype 
for sarcoidosis resolution, HLA-DRB1*04:01-DPB1*04:01 (resolved 16.9% 
vs. persistent 6.1%; p=0.02, OR = 3.1, 95% CI =1.15–8.41) which was 
independent of other HLA-DRB1 alleles. Our study showed that HLA-
DRB1*15:01 (sarcoidosis 41% vs. controls 28%; P= 0.016, OR= 1.76, 95 % 
CI=1.11-2.79) and HLA-DPB1*04:01 (sarcoidosis 66% vs. controls 55%; p= 
0.040, OR= 1.59, 95 % CI = 1.02-2.47) are general predisposing variants for 
sarcoidosis. The extended MHC haplotype analysis showed a predisposing 
effect for DRB1*15:01-DPB1*04:01 haplotype (25 % vs. 16 %; P= 0.04, OR= 
1.75, 95 %CI = 1.01-3.03). We could not successfully confirm the association 
of sarcoidosis with HLA-DRB1*11,  *12, and the CBD-related marker of HLA-
DPB1*02:01 (also known as Glu69) as reported by others [211,215,219]. Two 
protective HLA phenotypes were found: we successfully replicated the 
association of HLA-DRB1*01:01 (sarcoidosis 14% vs. controls 25%; P=0.008, 
OR=0.48, 95% CI = 0.27-0.83), and found a novel association with HLA-
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Table 10. Summary of significant associations between resolved and persistent 
sarcoidosis in the Finnish sample 






P value OR CI 95% 
DRB1*03:01 
phenotype 





16.7 6.1 0.02 3.07 1.13-8.29 
Arginine at position 74  DRB1*0301  34 16 0.007 2.70 1.35-5.37 
Tyrosine at position 26 DRB1*03:01, *09:01 39 24 0.027 2.10 1.10-3.40 
Lysine at position 71 DRB1*03:01, *04:01 48 31 0.017 2.10 1.14-3.77 





62 42 0.006 2.30 1.28-4.11 













29 45 0.025 0.50 0.27-0.91 








57 79 0.002 0.36 0.19-0.65 
Absent of DPB1*04:02 
and presence of 
rs2075430 A allele 
DPB1*04:02 65 79 0.041 0.05  0.27-0.98 
Res, resolved sarcoidosis; Per,persistent sarcoidosis 
 
To more extensively investigate the association of MHC class II molecules, 
we studied the relation of HLA-DRB1 pocket residues and sarcoidosis. The 
amino acid sequence of selected HLA-DRB1 alleles shows the polymorphism 
in more detail (Fig. 19). The analysis revealed that peptide binding sites 11, 
13, 26, 28, 30, 47, 71 and 86, located in pockets 1, 4, 6 and 7, were associated 
with sarcoidosis. In contrast, peptide binding sites in positions 26, 37, 67, 70, 
71 and 74, located in pockets 4, 7 and 9, were critical for disease prognosis 
(Table 11). Most interestingly, we showed that the arginine at position 71 was 
more common in patients with persistent disease, compared with the group 
with a resolved disease (see Table 11). 
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Figure 19 The amino acid sequences of HLA-DRB1*01:01, *03:01, *04:01 and *15:01 show a 
regions with variability. The sequences have been adopted from MGT/HLA 
Database. Sequence Alignment: Release 3.14.0 (2013-10-01) [78] 
5.2.2 IS THE C4 ASSOCIATION REFLECTING UNDERLYING LD 
STRUCTURE? (II) 
In addition to the traditional HLA genes, many promising non-HLA 
associations with different disease phenotypes and in different ethnic groups 
have been reported (summarized in Table 2). First, we studied the gene copy 
number of complement genes C4A and C4B, located within the MHC class 
III, as a novel susceptibility marker for sarcoidosis (Study II). The products 
of complement genes C4A and C4B, contribute in classical and lectin 
complement activation pathways, and the C4 deficiencies have been 
previously associated with a number of autoimmune, inflammatory or 
infectious diseases [142,155,252,277,278,283,284]. The study set consisted of 
188 Finnish sarcoidosis cases and 150 controls. The gene copy numbers of 
C4A and C4B and the CT insertion in C4A were detected with RT-PCR. Two 
subjects, one patient and one control, failed in the RT-PCR analysis, and 
were excluded. 
The gene copy number of C4A and C4B and C4-DRB1 haplotypes 
associated with sarcoidosis showed both predisposing (e.g., C4A*1-C4B*1-
DRB1*15:01) and protective (e.g. C4A*2-C4B*0-DRB1*01:01) associations 
(Table 11). However, the logistic regression analysis indicated that C4 
associations were likely to be due to the haplotype structure with HLA-DRB1. 
Interestingly, with the extended MHC haplotype analysis we identified a 
novel, but rare, HLA-DRB1*03:01 haplotype with one C4A gene that was 
associated with resolved disease (C4A*1-C4B*1-DRB1*03:01, p = 0.031, OR = 
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 DRB1*01:01:01      GDTRPRFLWQ LKFECHFFNG TERVRLLERC IYNQEESVRF DSDVGEYRAV TELGRPDAEY WNSQKDLLEQ RRAAVDTYCR HNYGVGESFT VQRRVEPKVT "
 DRB1*03:01:01:01   --------EY STS------- -----Y-D-Y FH----N--- ------F--- ---------- ---------- K-GR--N--- -----V---- -----H---- "
 DRB1*04:01:01      --------E- V-H------- -----F-D-Y F-H---Y--- ---------- ---------- ---------- K--------- ---------- -----Y-E-- "
 DRB1*15:01:01:01   ---------- P-R------- -----F-D-Y F--------- ------F--- ---------- ------I--- A--------- -----V---- -----Q---- "
 AA Pos.                   110        120        130        140        150        160        170        180        190        200 "
 DRB1*01:01:01      VYPSKTQPLQ HHNLLVCSVS GFYPGSIEVR WFRNGQEEKA GVVSTGLIQN GDWTFQTLVM LETVPRSGEV YTCQVEHPSV TSPLTVEWRA RSESAQSKML "
 DRB1*03:01:01:01   ---------- ---------- ---------- ---------T --------H- ---------- ---------- ---------- ---------- ---------- "
 DRB1*04:01:01      ---A------ ---------N ---------- ---------T ---------- ---------- ---------- ---------L ---------- ---------- "
 DRB1*15:01:01:01   ---------- ---------- ---------- --L------- -M-------- ---------- ---------- ---------- ---------- ---------- "
 AA Pos.                   210        220        230 "
 DRB1*01:01:01      SGVGGFVLGL LFLGAGLFIY FRNQKGHSGL QPTGFLS       "
 DRB1*03:01:01:01   ---------- ---------- ---------- --R----       "
 DRB1*04:01:01      ---------- ---------- ---------- -------       "
 DRB1*15:01:01:01   ---------- ---------- ---------- -------"
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P value OR  95% CI 
C4A genes < 2 # 25 16 0.059 1.75 1.01-3.02 
Haplotype: One C4A gene, one 
C4B gene, DRB1*15:01 
20 11 0.004 1.92 1.24-2.97 
C4A genes = 3 13 28 0.001 0.83 0.74-0.93 
C4B genes  < 2  29 41 0.021 0.58 0.37-0.91 
No C4B gene 4 10 0.026 0.35 0.14-0.88 
Haplotype: Two C4A genes,  
No C4B gene, DRB1*01:01 
3 10 <0.001 0.29 0.14-0.57 
#Including C4A insert if present 
 
Typically, HLA-DRB1*03:01 is found in an extended MHC haplotype with 
the C4A deficiency (AH.8.1). Surprisingly, only 66% of all HLA-DRB1*03:01 
alleles in the group with resolved sarcoidosis were inherited with the AH 8.1 
haplotype [1], compared with 89% in persistent disease.  It is therefore 
reasonable to speculate that the causal variant for sarcoidosis is in fact the 
HLA-DRB1*03:01 allele (or another, unknown variant in LD with HLA-
DRB1*03:01) and not the AH 8.1 haplotype. 
5.2.3 REPLICATION OF BTNL2 SPLICE-SITE VARIANT IN 
SARCOIDOSIS SUSCEPTIBILITY (III) 
The association of BTNL2, a member of the immunoglobulin gene 
superfamily, with sarcoidosis has been studied in many populations with 
contradictory results [175,226,233,234,237]. The splice site variant A of 
rs2076530 located at the exon 5 could, in theory, result in abnormal T-cell 
regulation and antigen response [175]. In Study III with the Finnish sample 
(187 case and 150 controls; one resolved patient failed the SNP typing) we 
replicated the increase of carriership frequency of A (AA/AG) of rs2076530 
[(rs2076530 (A)] with persistent sarcoidosis (92.9%) when compared with 
controls (84.0%) (AA/AG genotype; p=0.039, OR=2.48). In addition, the 
genotype AA and the allele frequency of A were significantly associated with 
the phenotype (unpublished results: carrier of A allele: p=0.01, OR=1.62; AA 
genotype; p=0.048, OR=1.68).  
The strong LD between HLA-DRB1 and rs2076530, as observed in our 
study (Table 12), complicated the detection of the causal effect. Indeed, HLA-
DRB1*01 is in total LD (D’=1.0) with rs2076530 (G) and HLA-DRB1*03 and 
*15 in strong LD (D’>0.8) with rs2076530 (A). We were able to show an 
independent role for both BTNL2 rs2076530 (A) as a predisposing and MHC 
class II as a protecting (HLA-DRB1*01:01 and DPB1*04:02) marker in an 
extended MHC haplotype analysis, where HLA-DRB1, HLA-DPB1 and 
rs2076530 were combined, and in a logistic regression analysis.	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Table 12. The LD between BTNL2 rs2076530 MHC class II alleles (HLA-DRB1 and –




Sarcoidosis Resolved Persistent Controls 
rs2076530 A  G A G A G A G 
DPB1*01:01 0.7   0.8       0.9   
DPB1*02:01               0.4 
DPB1*03:01 0.4           0.8   
DPB1*04:01                 
DPB1*04:02               0.2 
DRB1*01:01   1.0   1.0   1.0   1.0 
DRB1*03:01 0.9   1.0   0.8   1.0   
DRB1*04:01   0.8   0.9   0.7   0.9 
DRB1*08:01 0.8   0.5   0.8   0.9   
DRB1*15:01 1.0   1.0   1.0   0.9   
D'>0.8, Strong LD; >0.4 D' < 0.8, Moderate LD; >0.2 D'< 0.4, Low LD 
 
5.2.4 COMMON AND POPULATION-SPECIFIC MHC VARIANTS 
ASSOCIATE WITH SARCOIDOSIS (IV)  
The aim of the Sarcoidosis Collaboration Study was to replicate the 
association of MHC SNP variants to sarcoidosisin Finnish sarcoidosis 
patients and to explore associations shared across different populations or 
population-specific features. We used the functional candidate gene 
approach to identify genetic susceptibility loci for sarcoidosis. The genes 
selected (AGER, LTA, TNF, BTNL2, HLA-DRA) were finemapped with tag-
SNPs covering the genes from 5’ to 3’ region. The previously replicated SNP 
rs2076530 was also included in Study IV.  
After assessing the association between SNPs and sarcoidosis in the 
discovery sample (188 cases and 150 controls) we performed a replication 
and meta-analysis in four European populations (a total of 805 sarcoidosis 
patients and 870 controls, including the Finnish discovery sample). To 
reduce the study heterogeneity, patients were subgrouped to Löfgren (LS) 
and non-Löfgren patients (NL), and further to non-Löfgren resolved (NLR) 
and non-Löfgren persistent sarcoidosis (NLP) based on the disease outcome. 
The quality control procedure is detailed in Materials and Methods. 
Sixteen SNP were selected for replication, based on the analysis of the 
Finnish discovery sample. In the sample, 13 SNPs showed evidence of 
association (P < 0.05) with either NL  (seven SNPs; Fig. 20), LS (two SNPs) 
or the disease course of sarcoidosis (six SNPs). Three additional SNPs 
(rs3130349, rs1800624 and rs3135365) were selected based on nominal 
evidence of association. Furthermore, in the discovery sample, the strongest 
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evidence of association was observed with NL and rs3177928 (HLA-DRA; 
p=0.001, OR=2.17), and NL and rs28362677 (BTNL2; p=0.002, OR=1.92).  
 
 
Figure 20 Seven SNPs showed association (uncorrected P < 0.05) with non-Löfgren (NL) 
sarcoidosis in the Finnish discovery sample, the most significant being rs3177928 
(shown as a purple square in the fig.). Other SNPs are shown with dots; the color of 
the dots represents the extent of r2 with the most significant SNP, rs3177928. Data 
from the 1000 Genomes project was used for recombination rates and LD pattern 
[21].  
In the meta-analysis, several markers showed evidence of association with 
low heterogeneity (I2<25) (Table 13). In addition, population-specific MHC 
gene variants associating with the disease phenotype were found. The 
strongest association was for NL sarcoidosis and was detected with 
rs3177928 (P = 1.79E-07, OR=1.89, I2=0) near the HLA-DRA gene.  
In patients with LS or NL patients with resolved disease, the strongest 
association was observed in HLA-DRA gene with SNP rs3129843 (P= 3.44E-
12, OR=3.44, I2=11.54; P= 0.0029, OR=1.86, I2=12.78, respectively).  
Since the MHC region is known for its strong LD pattern, we investigated 
whether the MHC associated markers were independent of the association 
within the MHC region. We performed a conditional stepwise association 
analysis among the variants with P < 0.05 in the meta-analysis, using the 
HLA-DRB1 alleles as the covariate. Four of the observed variants near genes 
HLA-DRA and BTNL2 were independent of the HLA-DRB1 alleles, and were 
associated with distinct disease phenotypes with significant residual 
associations (bolded in Table 14). Furthermore, significant predisposing and 
independent variants for NL (vs. controls) were rs3135365, rs3177928, HLA-
DRB1*15 and the absence of HLA-DRB1*16; for LS (vs. controls), these were 
rs6937545 and HLA-DRB1*03, *13 and *14; and for NLR (vs. NLP), they 
were rs5007259 and HLA-DRB1*01. In addition, rs3135351 was independent 
of HLA-DRB1 alleles but not independent of rs5007259 (in analysis of NLR 
vs. NLR). However, some associations observed in the meta-analysis, like the 
association with rs3129843 and LS, were secondary to the HLA-DRB1*03:01 
allele (i.e., the SNP and HLA-DRB1*03:01 are in strong LD and the 
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association of HLA-DRB1*03:01 with the trait was more significant than with 
the rs3129843 SNP). 
 
Table 13. The meta-analysis of subjects in the Sarcoidosis Collaboration Study showed 
that variants in AGER, HLA-DRA and BTNL2 are associated with the disease phenotype (p<0.05, 
I2<25). When adjusting for HLA-DRB1, SNPs in the non-coding region of HLA-DRA and BTNL2 
remained significant (bolded) 
NL (n=629) vs. controls (n=859) 
SNP Gene(s) Function A1 A2 P(R) value OR I2  
rs1800684 AGER Coding exon A T 0.0034 0.73 0 
rs2076530 BTNL2 Coding exon A G 0.0003 1.34 0 
rs3763313 BTNL2 Promoter A C 1.24E-06 1.63 0 
rs9268528 BTNL2 Promoter A G 0.2450 0.91 0 
rs3135365 BTNL2/DRA   T G 0.009398 0.78 0 
rs3129877 HLA-DRA Intron A G 0.0197 0.82 3.3 
rs3135392 HLA-DRA Intron T G 0.0058 0.81 0 
rs3177928 HLA-DRA Downstream G A 1.79E-07 1.90 0 
                
LS (n=136) vs. controls (n=859)            







G A 2.03E-10 0.39 0 
rs1800624 AGER, PBX2 Promoter, 3' 
UTR 
T A 0.0013 1.70 0 
rs2076530 BTNL2 Coding exon A G 0.0086 1.45 0 
rs3763313 BTNL2 Promoter A C 0.0003 2.05 0 
rs5007259 BTNL2 Promoter T C 7.63E-07 1.99 0 
rs3129843 BTNL2/DRA   G A 3.44E-12 3.44 11.5 
rs9268644 HLA-DRA Intron A C 0.0010 1.69 21.3 
rs6937545 HLA-DRA Downstream A C 1.00E-09 2.28 0 
                
NLP (n=249) vs. NLP (n=337)           
SNP Gene(s)  Function A1 A2 P(R) value OR(R) I2  
rs28362677 BTNL2 Coding exon G A 0.0047 0.57 0 
rs5007259 BTNL2 Promoter T C 0.0412 1.28 0 
rs3135351 BTNL2/DRA   T G 0.0038 1.53 0 
rs3129843 BTNL2/DRA   G A 0.0030 1.86 12.8 
rs3129877 HLA-DRA Intron A G 0.0048 1.45 0 
 
To explore the extended MHC haplotypes more thoroughly, we created 
extended MHC haplotypes with HLA-DRB1 alleles and the 16 genotyped 
SNPs (Table 14 and 15). All the subjects that participated in the Sarcoidosis 
Collaboration Study and had the HLA-DRB1 genotypes available were 
included into the analysis (sarcoidosis patients n=461, controls=516). 
Subjects with missing SNP genotypes were excluded from the analysis. We 
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did not have the HLA-DRB1 status available for the Dutch sample set. The 
evidence favours the explanation that there is a wide range of polymorphism 
in the haplotypes. Furthermore, some of the variation is clearly due to 
population-specific features (Table 14). In Table 15, the full 16-SNP-DRB1 
haplotypes are presented, showing that polymorphisms in MHC class II-III 
region with particular HLA-DRB1 alleles are observed. It is reasonable to 
speculate that both the non-HLA genes (and HLA-DRA) and the antigen-
presenting molecule (HLA-DRB1) are needed for the susceptibility of 
sarcoidosis. Here, we did not perform a subphenotype analysis, due to 
sample size limitations.  
Table 14. The haplotype frequency (2n) of the 16-SNP-DRB1 haplotypes in Finnish (Fin), 
Swedish (Swe) and Czech samples (Cze) shows population specific differences both in 

























1 *01 0.06 0.14 0.03 0.08 0.03 0.05 
2 *01 0.01 0.01 0.01 0.02 0.02 0.02 
3 *03 0.12 0.09 0.19 0.12 0.13 0.09 
4 *04 0.06 0.08 0.08 0.10 0.03 0.03 
5 *04 0.05 0.03 0.06 0.05 0.05 0.06 
6 *07 0.03 0.02 0.01 0.01 0.03 0.04 
7 *07 0.01 0.01 0.01 0.04 0.01 0.03 
8 *07 - 0.01 0.02 0.04 0.01 0.04 
9 *08 0.08 0.11 0.04 0.02 0.02 0.02 
10 *08 0.01 - 0.01 0.01 0.01 - 
11 *09 0.01 0.01 - 0.01 - - 
12 *09 0.01 0.02 - - - - 
13 *11 0.06 0.04 0.05 0.03 0.06 0.08 
14 *11 - - 0.01 0.01 0.02 0.03 
15 *12 0.01 0.02 0.02 0.02 0.02 0.02 
16 *12 0.01 0.02 - - - - 
17 *13 0.03 0.05 0.03 0.02 0.04 0.01 
18 *13 0.03 0.03 0.02 0.04 0.02 0.01 
19 *13 0.03 0.02 0.01 0.01 0.04 0.03 
20 *13 0.01 0.01 0.02 0.01 0.03 0.03 
21 *13 - - 0.01 - 0.02 0.02 
22 *13 0.01 0.01 - - - - 
23 *14 0.01 - 0.02 0.02 0.02 0.02 
24 *14 0.01 - 0.02 0.01 0.03 - 
25 *15 0.17 0.11 0.10 0.10 0.13 0.10 
26 *15 0.03 0.03 0.03 0.03 0.03 0.01 
27 *15 - - 0.01 - 0.01 - 
28 *16 - 0.01 - 0.01 0.04 0.03 
NL, Non-Löfgren; LS, Löfgren syndrome 
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Table 15. Extended sixteen-SNP and HLA-DRB1 haplotypes in sarcoidosis patients (n= 
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In contrast to Study III, the BTNL2 (rs2076530) association did not reach 
the level of significance in the meta-analysis, after adjusting for the HLA-
DRB1 alleles. Furthermore, the SNP markers associated with disease 
phenotypes and showing heterogeneity (I2>25) indicated that population-
specific associations may occur. Table 16 presents the results of a case-
control association analysis within each population, using three different 
disease phenotypes (NL, LS, NLR and NLP).  
Table 16. Several SNPs showing significant (or nominal) evidence of association in the 
discovery sample (in three different analyses) were replicated in at least one of the European 
studies participating in the Sarcoidosis Collaboration Study. In addition, population-specific 
association were observed. 
Non-Löfgren (NL) sarcoidosis vs. Controls  
NL vs. Control Finnish 
(168 
vs.150) 
  Swedish 
(112 vs. 
358) 
  Dutch 
(180 vs. 
180) 




SNP(gene) P OR P OR P OR P OR 
rs3130349 
(AGER) 
0.284 0.79 0.1016 1.44 0.5873 1.11 0.7372 1.07 
rs1800684 
(AGER) 
0.016 0.60 0.1145 0.71 0.6758 0.91 0.1328 0.71 
rs1800624 
(AGER) 
0.670 0.93 0.07818 0.75 0.9788 1.00 0.9455 1.01 
rs28362677 
(BTNL2) 
0.002 1.92 0.1849 1.37 0.000156
3 
2.48 0.4551 1.18 
rs2076530 
(BTNL2) 
0.040 1.41 0.05729 1.35 0.2079 1.22 0.03493 1.40 
rs3763313 
(BTNL2) 
0.008 1.63 0.02956 1.57 0.02766 1.54 0.006012 1.84 
rs5007259 
(BTNL2) 
0.024 1.43 0.01265 1.47 0.8397 0.97 0.000805 1.68 
rs9268528 
(BTNL2) 
0.182 0.80 0.9733 0.99 0.2507 0.84 0.9078 1.02 
rs3135365 
(BTNL2/DRA) 
0.085 0.70 0.06114 0.71 0.3698 0.84 0.4726 0.87 
rs3135351 
(BTNL2/DRA) 
0.474 1.15 0.5828 0.90 0.5807 0.90 0.08462 1.42 
rs3129843 
(BTNL2/DRA) 
0.214 1.37 0.2343 0.74 0.4393 0.84 0.7248 1.10 
rs9268644 
(DRA) 
0.878 0.98 0.8369 1.03 0.1 0.78 0.07208 1.32 
rs3129877 
(DRA) 
0.104 0.76 0.1016 0.76 0.07022 0.75 0.6903 1.07 
rs3135392 
(DRA) 
0.016 0.68 0.149 0.80 0.1105 0.78 0.9523 0.99 
rs3177928 
(DRA) 
0.001 2.17 0.004588 2.10 0.01985 1.64 0.01984 1.85 
rs6937545 
(DRA) 
0.057 1.36 0.08723 1.31 0.422 0.88 0.01959 1.44 
NL,Non-Löfgren; LS,Löfgren; NLR,non-Löfgren syndrome and resolved disease; NLP,non-Löfgren 
and persistent disease 
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  Swedish (78 
vs. 358) 
  Dutch  
(- vs. -) 




SNP P OR P OR P OR P OR 
rs3130349 
(AGER) 
0.199 0.58 2.17E-08 0.35 - - 0.001061 0.42 
rs1800684 
(AGER) 
0.199 0.58 0.3968 1.28 - - 0.04788 3.17 
rs1800624 
(AGER) 
0.279 1.54 0.0248 1.65 - - 0.03247 1.87 
rs28362677 
(BTNL2) 
0.6135 1.25 0.06064 1.74 - - 0.1497 0.63 
rs2076530 
(BTNL2) 
0.2144 1.59 0.01271 1.59 - - 0.5734 1.16 
rs3763313 
(BTNL2) 
0.1475 1.87 0.001464 2.38 - - 0.1685 1.68 
rs5007259 
(BTNL2) 
0.03544 2.14 0.0001564 1.99 - - 0.01157 1.94 
rs9268528 
(BTNL2) 












0.2432 1.75 7.74E-12 3.78 - - 5.29E-06 3.85 
rs9268644 
(DRA) 
0.2353 1.53 0.04055 1.44 - - 0.0006642 2.34 
rs3129877 
(DRA) 
0.6495 0.85 0.0008453 1.81 - - 1.10E-06 3.38 
rs3135392 
(DRA) 
0.295 0.70 0.09121 1.35 - - 1.26-05 2.99 
rs3177928 
(DRA) 
0.1489 2.39 0.0006253 3.39 - - 0.841 1.08 
rs6937545 
(DRA) 
0.00988 2.43 6.30E-05 2.03 - - 3.20E-05 2.83 
rs3177928 
(DRA) 
0.8042 1.10 0.7893 1.16 0.6259 1.17 0.04049 0.38 
rs6937545 
(DRA) 
0.004038 1.89 0.9734 1.01 0.4446 1.18 0.8744 0.96 
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non-Löfgren syndrome and resolved disease (NLR) vs. non-Löfgren and persistent disease (NLP) 
NLR vs. NLP Finnish 
(79 vs. 89) 
  Swedish 
(33 vs. 75) 
  Dutch  
(90 vs. 
90) 
  Czech (47 
vs. 83) 
  
 SNP P OR P OR P OR P OR 
rs3130349 
(AGER) 
0.3541 0.76 0.5253 0.76 0.2175 0.71 0.4221 1.30 
rs1800684 
(AGER) 
0.2179 0.72 0.9727 1.01 0.6603 1.14 0.5487 0.80 
rs1800624 
(AGER) 
0.07906 1.51 0.1758 0.66 0.7198 1.09 0.189 1.44 
rs28362677 
(BTNL2) 
0.05861 0.54 0.8676 0.93 0.02773 0.39 0.1777 0.60 
rs2076530 
(BTNL2) 
0.2253 0.75 0.3836 1.31 0.5785 1.13 0.7644 1.09 
rs3763313 
(BTNL2) 
0.3511 1.29 0.6565 1.21 0.2377 0.70 0.4345 0.73 
rs5007259 
(BTNL2) 
0.2278 1.31 0.1877 1.49 0.2041 1.31 0.7914 1.07 
rs9268528 
(BTNL2) 
0.01434 1.78 0.4229 0.79 0.5176 1.15 0.2416 1.36 
rs3135365 
(BTNL2/DRA) 
0.2155 0.72 0.4867 1.29 0.2381 1.36 0.2187 0.68 
rs3135351 
(BTNL2/DRA) 
0.01629 1.85 0.2908 1.47 0.1212 1.50 0.5839 1.20 
rs3129843 
(BTNL2/DRA) 
0.00407 2.63 0.141 2.00 0.04417 2.00 0.9591 0.98 
rs9268644 
(DRA) 
0.004265 1.89 0.9672 1.01 0.5969 1.12 0.1256 1.49 
rs3129877 
(DRA) 
0.02308 1.71 0.6702 1.15 0.1675 1.38 0.1798 1.48 
rs3135392 
(DRA) 
0.2571 1.28 0.7688 0.91 0.2361 1.29 0.332 1.30 
rs3177928 
(DRA) 
0.8042 1.10 0.7893 1.16 0.6259 1.17 0.04049 0.38 
rs6937545 
(DRA) 
0.004038 1.89 0.9734 1.01 0.4446 1.18 0.8744 0.96 
 
Many of the SNPs that showed evidence of association with the trait in the 
Finnish discovery sample were replicated in the independent European 
samples. One can argue that the sample groups are rather small after 
subgrouping the patients according to disease phenotype. Hence, the 
association between the variant and trait did not always reach the level of 
significance, probably due to the limited sample size, highlighting the 
importance of using meta-analysis to obtain larger subgroups and more 
statistical power for future studies. We also discovered clear population-
specific differences between the analyses.  Most importantly, the exonic 
BTNL2 SNP rs28362677 was replicated in the Dutch sample, showing strong 
evidence of associating with both sarcoidosis and with the disease course (P 
= 0.00016, OR=2.48; P = 0.028, OR= 0.39, respectively), which was not seen 
in the Swedish or Dutch sample. 
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The SNP LD blocks analysis of Finnish, Swedish, Dutch and Czech 
samples confirms the population-specific LD patterns, indicating that the 
Swedish have more conserved and longer LD patterns in MHC class II-III 
region than, for example, the Dutch  (Fig. 21). 
 
 
Figure 21 The extended SNP block (r2) in Swedish sarcoidosis patients (NL+LS) is longer 
than in the Dutch sarcoidosis patients (NL+LS), suggesting population-specific 
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6 DISCUSSION  
6.1 MHC PROFILE OF THE FINNS 
Extended MHC haplotyping is a valuable tool for detecting disease 
association as well as anthropological studies. It provides a deeper 
understanding of the associations found in the MHC region and assists in 
characterizing the differences in LD structure between different populations 
[50,86,272,275,285]. The results of Study I provided new information about 
the correlation between traditional HLA alleles and MHC variants in the 
Finnish sample. The Finns’ extended MHC haplotypes, covering both 
traditional HLA genes and non-HLA genes, have not been investigated before 
in depth. Although no novel alleles were detected in this study, the Finnish 
allelic and common haplotypic MHC profile was characterized.  
The enrichment of A*03-B*35-DRB1*01 haplotype and the infrequency of 
the common European haplotype, A*01-B*08-DRB1*03, (AH 8.1) represents 
the unique genetic heritage of the Finns [112,286,287]. The 16th 
International HLA and Immunogenic Workshop IHIW project “Analysis of 
HLA Population Data” [112], in which we collaborated, performed the HLA 
allele frequency comparisons between populations. The results showed that 
the Finns and the Sami were genetically closer to the North-East Asians than 
to other European populations corresponding to the previous non-HLA 
anthropological analyses [112,287]. Overall, the similarities between the 
Finns and the Sami indicated that the distribution of HLA alleles follows the 
north-to-southeast axis, which is comparable with the previous Finnish HLA 
studies, which show large regional variations between different geographical 
areas of Finland. These regional differences may be caused by natural 
barriers such as lakes or a particular immune response to a particular 
pathogen [288,289]. Whereas the previous publication of the regional HLA 
diversity in Finland was mainly based on serological typing [288], a more 
comprehensive study of the MHC regional variation (of both HLA alleles and 
extended haplotypes) should be conducted [288,290].  
The main result of this study was the Finnish MHC profile, together with 
the two-locus haplotype map presented in Fig. 21, which characterizes the 
diversity of the Finnish MHC haplotypes in relation to HLA-DRB1. The MHC 
profile, togeth with the haplotypes of HLA-DRB1, can be used as guidance to 
explore the common allelic diversity of the neighbouring genes and the LD 
pattern of the region. Moreover, population specific haplotypes can lead to a 
better understanding of disease risk [224,255]. The widespread variation 
observed in the MHC profile provides essential information of the LD 
structure, which assists the interpretation of association signals in human 
traits and suggests   future studies. For example, if the most significant SNP 
is localized at the ‘3 end of HLA-DRB1 gene, and HLA-DRB1*15 is previously 
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suggested as a disease susceptibility variant, one could recommend not to 
further analyse BTNL2 or HLA-DQB1 loci that are almost always in tight LD 
with HLA-DRB1*15. This makes detectingthe independent effect a 
challenging task, but instead analysing HLA-DPB1, which shows wider allelic 
diversity and multiple different haplotypes with HLA-DRB1*15 allele. 
Moreover, the characterization of the HLA-DRB1*03 haplotypes in the Finns 
agreed with the previous observation that most of the polymorphisms of the 
DR-haplotype are observed in either the 5’ end (near HLA-A) or the 3’ region 
(near HLA-DPB1). The need to adjust for HLA alleles and to analyse residual 
associations can also be estimated with the knowledge of population-specific 
MHC profiles. The VITA sample, representing the Finnish population and 
used in this study, was collected in Helsinki, Finland, and the distribution of 
the traditional HLA alleles was consistent with the previously published 
reports including thousands of Finnish individuals from a registry for bone-
marrow transplantations (BMTs) [288,290,291]. This suggests that a 
population’s common HLA allele frequencies can be estimated with modest 
sample collected from metropolitan area, such as the one used in this study. 
However, as mentioned before, regional differences exist, and warrant more 
studies. 
The population-specific haplotypes are also advantageous for matching 
patients for transplantation and may reveal regional restrictions for the HLA 
alleles [264,292]. As an example, Eastern European Americans and Eastern 
Europeans share similarities in the HLA-DRB1 frequency, but the multi-
locus haplotypes display regional differences between them [264,293]. In 
addition, understanding the full HLA profile of a population can lead to 
better stratification of individuals (e.g., for control selection) that share 
common genetic heritage. The knowledge of a population’s MHC profile 
distribution may also improve the HLA matching in transplantation. With 
the ancestry information, the donors HLA haplotypes can be predicted from 
low-resolution types [120,294].  
Multi-population collaborations to collect HLA-typing information from 
different populations and subpopulations allow illustrating detailed MHC 
profiles and genetic maps of the human population, as well as estimating 
regional differences within the population. To date, Europe is well 
characterized for HLA data, while only a few HLA-typed population samples 
are available from Africa.  The HLA genetic landscape of Africa offers a huge 
potential to detect widespread variation in the MHC and may provide novel 
insights into the human past [112,289,293,295,296]. 
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Figure 22 The MHC profile in the Finnish population presented as two-locus haplotypes in 
relation to HLA-DRB1. The frequency (%) of HLA-DRB1 haplotypes (observed > 3) 
and traditional HLA alleles (HLA-A, -B, -DQB1 or -DPB1) or MHC class III blocks 
(TNF, C4 and BTNL2; observed n > 3) shows that the allelic diversity varies in 
relation to different HLA-DRB1 alleles. The haplotype map illustrates, for example, 
that the HLA-DRB1*15:01 allele is typically linked with HLA-A*02, HLA-B*07, 
TNF_1 block, complement C4_1 block, BTNL2_2 block, HLA-DQB1*06:02 and/or 
HLA-DPB1*04:01. 
6.2 THE MHC ASSOCIATION WITH SARCOIDOSIS   
This study confirmed the complex network of effects of several MHC genes to 
sarcoidosis susceptibility [164]. Based on the results, we suggest a genetically 
heterogeneous nature for sarcoidosis, showing that both locus heterogeneity 
(e.g. many variants in BTNL2 associated with sarcoidosis) and allelic 
heterogeneity (different genes associated with sarcoidosis), which can 
express the same disease phenotype. We succeeded in replicating the 
association of variants in HLA-DRB1 and BTNL2 (rs2076530) and detected 
novel variants in HLA-DPB1 that were associated with sarcoidosis or/and the 
disease course of sarcoidosis in the Finnish sample. In addition, SNP 
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significantly associated with sarcoidosis and shared among different 
populations in a joint case-control study of four European study samples. 
Previous studies have highlighted the importance of characterizing the 
patients into distinct clinical subgroups to avoid inconsistency between 
studies (e.g., [211,224]). Here, to investigate some of this phenotypic 
heterogeneity in sarcoidosis, we used a well-characterized patient group that 
had undergone follow-up for a mean of 15 years and where the patients were 
divided into subgroups based on the disease activity at a follow-up visit after 
the first two years. In addition, we collected additional European samples 
with equally extensive disease phenotyping, to explore variants that were 
shared among the populations in order to better understand the mechanism 
of sarcoidosis immunopathogenesis and increase the power of the study. 
Indeed, environmental triggers are undoubtedly needed for predisposition to 
sarcoidosis [2], but unfortunately no specific exposure data was available in 
this study. 
Due to the lack of validated population-specific biomarkers in Finland, 
the prognosis of sarcoidosis is currently based solely on the clinical picture 
[180]. In Sweden, the HLA-DRB1*03 allele is used in screening of patients 
with favourable outcome [192]. If the disease course of sarcoidosis could be 
estimated with gene susceptibility markers, patients with a risk to develop 
the chronic form could be recognized at an early stage and treated better. In 
practice, if a patient has a genetic marker of good prognosis, the treatment 
may not be initiated in hope of a spontaneous remission. The genetic 
markers of poor prognosis would promote proper targeting of follow-up 
visits and early treatment.  
6.2.1 MHC CLASS II AND SARCOIDOSIS 
In this study, the MHC class II genes were investigated as susceptibility 
markers for sarcoidosis, because: (i) HLA-DRB1 has been shown to associate 
with sarcoidosis in many populations and with distinct disease phenotypes, 
and had not been studied in the Finnish sample, (ii) the studies of HLA-DPB1 
in sarcoidosis susceptibility have given contradictory results, and (iii) the 
HLA class II genes encode the molecules on the surface of APCs that bind 
and present antigens to the T cells.  Most importantly, we agreed that for 
resolved sarcoidosis, variants in the HLA-DRB1 gene, especially HLA-
DRB1*03:01 (allelic association and association with peptide-binding sites), 
are essential for disease predisposition. However, HLA-DRB1*03:01 allele is 
not as common in Finnish patients as it is among their Swedish counterparts, 
with carrier frequencies of 19% and 29%, respectively (unpublished results 
from Study IV). An increasing number of studies has confirmed the 
importance of HLA-DRB1*03:01 on LS and resolved sarcoidosis 
susceptibility in patients with European descent [224,297-300].  However, in 
Japan the HLA-DRB1*03 allele is rare, potentially explaining the non-
association of the variant with sarcoidosis [183]. In the Finnish patients, the 
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HLA-DRB1*15:01 allele did not show association with persistent sarcoidosis, 
as previously observed in various populations of European descent 
[211,224,229,301]. Thus, it is perhaps reasonable to hypothesize that the 
HLA-DRB1*15:01 should not to be used for estimating the prognosis of 
chronic sarcoidosis in the Finnish population. Furthermore, the protective 
MHC class II alleles (HLA-DRB1*01:01 and HLA-DPB1*04:02) have shown 
evidence of association with other autoimmune or infectious diseases as well: 
HLA-DRB1*01 predisposes for recurrent lymphocytic meningitis, coronary 
artery disease and juvenile idiopathic arthritis, while HLA-DPB1*04:02 has 
been shown to be a protective marker for T1D [155,278,302-304]. For 
chronic sarcoidosis, we did not discover any predisposing HLA-DRB1 or –
DPB1 alleles; however, the lack of protective alleles, especially in HLA-
DPB1*04:02, shed light on the importance of MHC class II on disease 
predisposition. Moreover, HLA-DPB1 is strongly associated with CBD, a 
granulomatous disease clinically and pathophysiologically similar to chronic 
sarcoidosis [219,305].  
In the meta-analysis, some genotyped variants near the HLA-DRA 
promoter region were associated independently of HLA-DRB1 with 
sarcoidosis or its disease course. The noncoding region of HLA-DRA contains 
important regulatory elements, including a promoter region and enhancer 
sequences, which can modify the expression of the protein. The HLA-DRA 
association to sarcoidosis has been shown previously, but the variants 
detected in Study IV were novel. In addition, HLA-DRA and another 
sarcoidosis susceptibility gene, ANXAII, have been suggested to have gene-
gene interactions [237,242,244]. To explore the association more thoroughly, 
studies with dense SNP sets in large samples from multiple ethnic groups are 
warranted. 
6.2.2 BTNL2 AND SARCOIDOSIS 
In this Finnish sarcoidosis study, we replicated the association with the 
exonic missense variant of BTNL2 (rs2076530) [175] with a poor outcome of 
sarcoidosis, in agreement with previous studies from German, Danish, 
British, Dutch study samples [175,233,234,306]. Furthermore, the high-risk 
A-allele of the splice-site variant (rs2076530) results in a truncated protein, 
which has atypical membrane localization [175,307].   BTNL2 is expressed in 
APCs, e.g. dendritic cells in the spleen and lymph nodes [308], and is 
involved in T-cell activation. BTNL2 regulates the immune response by 
inhibiting T cell proliferation and reducing the production of 
proinflammatory cytokines. Hence, the dysfunction of BTNL2 could result in 
an uncontrolled activation of T cells, which is observed in sarcoidosis 
[180,232,308].  
The SNP rs2076530 is probably the most studied variant of the BTNL2 
gene. However, other variants of BTNL2 gene have been associated with 
sarcoidosis as well [230,309]. In this study, the finemapping of the BTNL2 
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gene revealed additional variants in the BTNL2 promoter region, which were 
significantly associated with different sarcoidosis phenotypes in the meta-
analysis combining Finnish, Swedish, Dutch and Czech samples. In addition, 
population-specific BTNL2 associations with sarcoidosis phenotypes were 
found (e.g., rs28362677). In the meta-analysis, the rs2076530 association 
with sarcoidosis vanished after population stratification and adjusting for 
HLA-DRB1 alleles, most probably due to the observed strong LD between 
BTNL2 and HLA-DRB1. Indeed, the Swedish sample produced a strong LD 
pattern in MHC class II region, which probably dominated the meta-analysis, 
leading to a lack of association to rs2076530. Furthermore, several studies 
have attempted to distinguish whether BTNL2 or HLA-DRB1 is responsible 
for the association to sarcoidosis. A recent Portuguese study [299] showed a 
phenotype-specific association of BTNL2 variant rs2076530 in patients 
without Löfgren syndrome (NL sarcoidosis). Thus they reported that the 
association was secondary to HLA-DRB1 in patients with Löfgren syndrome. 
Again, the associations of BTNL2 with other autoimmune diseases, including 
T1D [235] and MS [301], have been shown to be secondary to other genes, 
mostly the HLA class II alleles. This strongly supports the importance of 
genotyping HLA-DRB1, and adjusting the BTNL2 associations with HLA 
class II alleles [192,299]. We may speculate that the discrepancies in the 
association between BTNL2 variant rs2076530 and sarcoidosis may be due 
to heterogeneity in the distributions of alleles in different populations or 
differences in the study design [175,220,230,233,299,307].  
In summary, the importance of BTNL2 in sarcoidosis predisposition is 
robust. The dysfunction of BTNL2 protein has is a biologically plausible 
mechanism for sarcoidosis (impairing normal T-cell regulation and response 
to antigens) and variants of BTNL2 has been associated with different 
sarcoidosis phenotypes in different populations. In this study, we not only 
replicated the association of BTNL2 variant rs2076530 with persistent 
sarcoidosis in Finns, but our study highlighted the importance of BTNL2 in 
sarcoidosis susceptibility in general. Based on the comprehensive analysis of 
BTNL2 as sarcoidosis susceptibility variant, we indicated that the 
combination of modified T cell regulation due to BTNL2 (e.g., splice-site 
BTNL2 variant rs2076530) and the lack of the protective MHC class II alleles 
(antigen-presentation) are needed for susceptibility to chronic sarcoidosis 
[226,233,306,310]. For resolving sarcoidosis, we suggest focusing on 
exploring the widespread variation in the BTNL2 promoter region and multi-
gene haplotypes including BTNL2. It is tempting to speculate that different 
variants of BTNL2 are present only in certain populations (locus 
heterogeneity), which suggests that different BTNL2 genotypes can be 
expressed as the same disease phenotype, contributing to the lack of 
replication of the rs2076530 association in some studies.  
To conclude, this study illustrated the power of combining well-
characterized patients with specialized MHC analysis. However, to validate 
the role of the MHC variants for disease prognosis of sarcoidosis, the genetic 
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signals should be confirmed in larger samples and using different techniques, 
before they can be used in a clinical setting in Finland. For example, it is 
essential to investigate the expression of the BTNL2 transcript in target cells 
including the disease-associated missense SNP rs28362677 or study the 
effect of the promoter SNPs in BTNL2 expression. As there is no well-
established animal models for sarcoidosis and as the disease is rather rare 
disease in the European population, collaboration studies are needed to 
obtain larger samples sizes, and thus strongly encouraged. 
6.3 THE EXTENDED MHC HAPLOTYPE ANALYSIS IS 
ADVANTAGEOUS FOR COMPLEX DISEASE 
STUDIES 
For many autoimmune and infectious traits, among them sarcoidosis, the 
strong linkage/association with MHC was discovered decades ago. A typical 
feature for HLA association is that the any associated variant is common in 
healthy subjects. For example, the general predisposing allele for sarcoidosis, 
HLA-DRB1*15:01, is the most common allele in the Finnish population (I, 
II); approximately 30 % of the Finnish sample has at least one copy of HLA-
DRB1*15:01, and the same allele can act both as a predisposing (for 
narcolepsy, sarcoidosis and MS) and a protecting (for T1D) allele [311]. 
Interestingly, multiple autoimmune diseases tend to track in the same 
patients and same families. Obviously, contribution of additional genes and 
the poorly understood environmental triggers are necessary for disease 
predisposition [312].  
To understand the genetic and functional basis of the susceptibility 
variant(s) in MHC, approaches should be employed. As a primary finding, 
this study showed that by genotyping multiple genes in MHC and 
establishing the extended MHC haplotypes, additional 
predisposing/protective associations between markers and trait not 
detectable with a single MHC allele could be detected (I, II, III, IV). Firstly, 
HLA-DRB1*04:01 was not itself associated with the disease course of 
sarcoidosis, but haplotype HLA-DRB1*04:01-DPB1*04:01 was (III). Without 
the meta- and multi-gene analysis, the independent effects of novel BTNL2 
and HLA-DRA variants could not have been observed due to strong LD 
between BTNL2 and HLA-DRB1 in Finland (I, IV). Secondly, the HLA-
DRB1*03:01 allele, not the AH 8.1 haplotype [1], was suggested as the most 
prominent causal variant for resolving sarcoidosis, and would not have been 
properly identified without genotyping multiple genes (II). Thirdly, different 
extended MHC haplotypes can lead to functional similarities, including C4 
deficiency or a truncated form of BTNL2, which can be informative for 
disease association studies (I) [175,258,283,284]. 
An additional important aspect in MHC studies is to understand the 
possible functionality of the associating variant for the trait. Polymorphisms 
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in the antigen binding sites of HLA genes define the antigen(s) that can be 
presented in T cells. Variation in the peptide-binding sites of MHC molecules 
may alter the peptide-MHC interactions and determine which peptides can 
be bound in the first place [313-315]. It is essential to recognize that similar 
binding-ability can be observed with different MHC alleles. In our 
sarcoidosis study, the peptide-binding analysis of HLA molecules clearly 
indicated that the allelic association of HLA genes does not explain 
everything, suggesting that it is highly recommended to explore the peptide-
binding repertoire of the HLA alleles that can be shared between different 
alleles, as shown with previous autoimmune studies with, e.g., RA and the 
shared epitope of HLA-DRB1 [149,255,316]. Although the primary HLA-
DRB1 associations with sarcoidosis vary between studies and with different 
populations [187,211,215], the susceptibility/predisposing alleles can affect 
identical peptide binding sites that vary the ability to bind specific antigens 
[215,314,317,318]. The peptide binding pockets can have distinct chemical 
and size characteristics, but any polymorphism of the peptide-binding site 
can still change the T-cell recognition or have an effect on the peptide 
binding affinity [255]. In the case of sarcoidosis, the specific antigen is still 
unknown, and the next challenge is to identify the antigens that the 
molecules present to CD4+ T cells. It is possible that the antigens differ 
across distinct sarcoidosis phenotypes or ethnicities [187,211]. The discovery 
of sarcoidosis-associated antigens could improve the therapy for sarcoidosis.  
In addition, many MHC association studies have suggested susceptibility 
markers for autoimmune and inflammatory traits that are located outside the 
peptide encoding sequence, and can thus affect epigenetic factors, such as 
microRNAs that modulate the immune response, methylation sites or 
binding sites of transcription factors. These studies require more 
sophisticated analyses [25,168]. The non-replication of variant can be caused 
by, e.g., population-specific differences, false negatives due to small sample 
size, heterogeneous replication samples and complex LD structure [233,319]. 
Our results agree with recent studies showing that the recombination 
hotspots in MHC vary between populations [2,273,286,287]. Considering the 
hampering effect of LD, it is highly possible that not all published MHC 
associations with sarcoidosis are true. The power of these genetic studies can 
be increased by increasing the size of the study sample, as done in Study IV, 
combined with accurate phenotyping to lower sample heterogeneity [187].  
6.4 CHALLENGES IN MHC ANALYSIS 
A comprehensive analysis of the MHC region still remains a daunting 
challenge due to structural rearrangements, pseudogenes and the LD 
structure. Typical MHC datasets contain a variety of types of genotype 
information (multiallele HLA genes, SNP or gene copy number data) from 
different laboratories, with varying nomenclature and genotyping methods 
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[265,320]. The HLA allele calling and resolution of multiple ambiguous alleles 
and genotypes requires expertise in both the MHC locus and the population 
in question, and if the data have not been generated and analyzed properly, 
ambiguity can lead to major inconsistencies between datasets and spawn 
false results [321]. In this study, the MHC genotypes were obtained using five 
different genotyping approaches. To avoid inconsistency in the data, all the 
genotypes were corroborated by at least two researchers, and the HLA alleles 
were called with the same nomenclature. In Study IV, we received 
heterogeneous typing results from three different countries, which were then 
standardized by converting all the allele data to the lowest resolution (2-
digit) [85,293]. In Study IV, we collected additional international samples 
with mutual extensive disease phenotyping, and performed a successful 
meta-analysis discovering variants that were shared between the 
populations, to assist us to better understand the mechanism of sarcoidosis 
immunopathogenesis. 
For discovering novel susceptibility loci associating with the trait, 
especially outside the MHC region, GWAS offer a cost-effective model by 
testing a large amount of variants in a large number of patients [82]. In the 
case of small sample sizes and/or heterogeneous samples, GWASs have had 
trouble with low statistical power to discover rare variants or with multi-
allelic data [212,237]. Our work aimed to study solely the MHC region alone, 
and replicate the knowm MHC variant(s) in an independent sample (the 
Finnish study sample) using a functional candidate gene case-control 
approach. The candidate gene studies are biased, however, as they require 
prior information regarding gene function and gene variations, and are 
sensitive to population stratification. Here, the best functional candidate 
genes in the MHC region were selected using both previous publications and 
the MHC haplotypic profile of the Finns (Study I). 
Finding the proper analysis method for immunogenomic data is tricky, as 
most of the available statistical approaches (e.g. PLINK [257]) were originally 
developed to deal with biallelic polymorphism (SNPs). The immunogenetic 
data warrants tools that can handle the extensive LD within MHC and 
multiple genes with multiple alleles. To date, there are no single tools 
available that can perform all the analyses needed for immunogenetic data. 
First, due to the complexity of the region, the HLA allele calling needs to be 
performed with specific software, typically a commercial one (e.g., ASSING, 
SCORE). Second, to conduct MHC haplotypes analysis and calculate the LD 
between loci, further specialist tools, e.g., PHASE [263] and Arlequin [260], 
are needed.   
The previous studies have highlighted several issues that should be 
addressed in immunogenetic data analysis, including the cut-off values for 
low-frequency variants and the caution needed in interpreting LD between 
loci [84,104,112,265,321].  As suggested elsewhere [265], analytical 
interpretations should not rely on rare haplotypes. In this study, we used a 
haplotype frequency cut-off value, excluding haplotypes with frequency less 
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than 1%. Although possible false results were thus rejected, many potentially 
informative low-frequency haplotypes that may be important for disease 
association studies were excluded as well [265,293]. LD complicates inding 
the causal variant as many markers are in total LD (r2=1) while genes in 
conversed haplotypes (e.g., HLA-DRB1*15:01 is always with HLA-
DQB1*06:02 in the Finnish population) may have equivalent statistical proof 
of association. Moreover, the linkage and association signals can cover long 
haplotypes with alleles from multiple HLA genes [2,82]. As several different 
identifiers may exist for a single variant, this complicates comparing variants 
across studies [321]. The improper interpretation of LD (e.g., D’, is sensitive 
for rare alleles and r2 is not suitable for multi-allelic data analysis [265]) can 
create misleading results, and thus it is important to explore results using a 
variety of LD measures and take into account the allele counts, as we did in 
Study I. Again, the strong LD within MHC and the heterogeneity of 
sarcoidosis phenotypes complicates the interpretation and detection of 
causal variants. Most importantly, in many studies the degree of LD with 
HLA class II alleles and adjusting for disease phenotypes have not been 
stratified [306], potentially leading to discrepancies between studies [299]. 
Furthermore, the adjustments can change the association with the reported 
variants, as shown in the study of Spangolo et al [233], where the rs2076530 
association with sarcoidosis vanished after adjusting for HLA-DRB1 alleles 
and exclusion of genetically district disease group (LS). To note, Valentonyte 
et al. [175] did not exclude the patients with Löfgren syndrome from their 
studies. 
The current HLA typing methods are targeted approaches, requiring the 
amplification of specific HLA gene segments. With innovative NGC 
techniques (whole genome, whole exome and transcriptome sequencing), 
multiple HLA genes can be sequenced at once while preserving phase 
information. However, the complexity of MHC warrants bioinformatics, 
scarcity of population-specific references and knowledge of the MHC region, 
and most likely commercial allele calling software, that are not widely 
available. [84,85,95,320]. One of the first publications using NGS data for 
HLA typing was performed with a Roche-454, using long reads from targeted 
sequencing data [84,95]. A recent study showed higher than 90% accuracy 
using NGS exome sequence (Illumina) of HLA class I genes [100]. In 
addition, recent NGS studies have been hampered with insufficient read 
depth in whole-genome and exome sequencing, highlighting similar MHC-
specific challenges in NGS than in traditional Sanger sequencing; (i) most 
subjects are heterozygous in MHC locus, making the alignment with the 
reference challenging, (ii) to date, thousands of known HLA alleles have been 
identified and, (iii) MHC region contains long, segmental duplications, 
heterodimeric proteins with several possible genes and pseudogenes 
[84,85,95,97,100-102,322]. Previously, a tag-SNP based HLA-typing method 
was suggested as an alternative solution for traditional HLA typing [82,86]. 
In some cases, the HLA tag-SNPs have been validated in a specific 
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population and used successfully instead of traditional HLA genotyping [89]. 
Due to the complexity of MHC region, the allele differences between 
populations and the lack of population-specific reference data complicates 
the tag-SNPing and can lead to false imputation results [27,82,323]. The 
SNPs in this study were initially selected to cover the genes in question, not 
to impute HLA alleles. However, we had the HLA-DRB1*15:01 tag-SNP 
present (rs3135388, r2=0.966, D’=0.993[86]), and found that in the Finnish 
sample, the LD between HLA-DRB1*15:01 and rs3135388 was complete (r2 
=1.00 and D’= 1.0). The SNP has been used to impute HLA-DRB1*15:01 in 
previous studies [282], but as far as we know no validation in a Finnish 
sample has been performed. Despite of the success of HLA-DRB1*15 
imputation, based on our unpublished data, the current SNP imputation of 
MHC markers is not suitable for detecting all polymorphism in the MHC 
region, especially in Finland. To detect Finnish tag-SNPs for HLA alleles, a 
large population sample with several HLA genotypes and dense SNP fine-
mapping in the MHC region is required, and this was not available at the 
time of our study.  
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7 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
The first MHC was defined in mice over 70 years ago [324], and the first HLA 
antigen MAC (later to become HLA-A2) was identified over 50 years ago 
[325]. The first correlation between HLA matching and kidney allograft 
survival was shown in 1965 and the first remarkable HLA disease association 
was detected between HLA-B27 and ankylosing spondylitis in 1972 [141,326]. 
Since then, the study of MHC genes in different species and in ethnic 
populations has dramatically increased, leading to many more identified 
MHC disease associations [84,327].  
Despite the genetic and epidemiological efforts, understanding the genetic 
basis of many MHC associated traits, such as sarcoidosis, still remains a 
mystery [82,176]. Furthermore, while the MHC genes have been the most 
extensively studied susceptibility genes in sarcoidosis, Finnish MHC studies 
of sarcoidosis did not exist prior to this study. Although the traditional HLA 
haplotype frequencies for the Finns have been published previously 
[288,291], the diversity of the extended MHC haplotypes had not been 
studied among the Finns. We hypothesized that the study of the Finns MHC 
profile and the extended MHC structure would be advantageous for 
pinpointing possible causal variant(s) for sarcoidosis. 
After analysing several HLA and non-HLA genes in Finnish subjects and 
SNPs in sarcoidosis collaboration study subjects, this study succeeded in the 
following five goals. 
1) The characterization of the MHC profile in Finnish population, using 
extended MHC haplotypes.  
2) The replication of known sarcoidosis-associated MHC markers in a 
Finnish sample 
3) The detection of novel associations between sarcoidosis phenotypes 
and MHC markers that were shared among populations 
4) The identification of novel population-specific MHC associations for 
sarcoidosis phenotypes  
5) Demonstration of guidelines for handling immunogenetic data 
 
The Finnish MHC profiles revealed certain population-specific MHC 
haplotypes with a length and LD structure that a unique in Finns. The study 
of extended MHC haplotypes enabled the creation of a two-locus linkage map 
in relation to HLA-DRB1 alleles, which illustrates a linkage between the two 
variants. In addition, distinct extended MHC haplotypes can lead to 
functional similarities, including C4 deficiency or a truncated form of BTNL2 
[175]. Thus, the rare HLA-DRB1 haplotypes that differ from the common 
haplotypes by, e.g., a particular TNF polymorphism, are potentially 
informative for future association studies.  
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All the main achievements in the sarcoidosis study promoted the 
importance of the MHC in sarcoidosis predisposition. Even though the 
Finnish sample in this study was limited in size, our study provides new 
insights to the disease prognosis, highlighting a particular distribution of 
MHC markers with some markers associated with different patterns of 
disease progression. For sarcoidosis, an immune-mediated inflammatory 
disease, the proper understanding of the complex etiology warrants further 
studies of the MHC in different ethnic groups, preferably via a meta-analysis 
of samples with well-characterized disease phenotypes. In addition, the non-
MHC variants that have shown to associate with sarcoidosis phenotypes 
(detected through GWASs) ought to be investigated in a Finnish study 
sample. Biologically, the most interesting of these candidate genes is annexin 
A11 on 10q22.3[242].   
Similarily to previously published work [84], this study agreed that the 
major challenges in MHC research are the complexity of the MHC region, 
including strong LD, heterogeneity of associated disease phenotypes, and 
population-specific MHC allele distribution. This strongly supports the 
importance of genotyping multiple genes in the MHC region and using the 
extended haplotype analysis for detecting causal variants for MHC-
associated diseases. Using this approach, novel sarcoidosis-associated MHC 
variants were identified, which would have otherwise been undetectable.  
To summarize, the MHC region offers considerable potential to discover 
predisposing and protective variants affecting autoimmune and infectious 
disease [168]. Analysis of the MHC region, however, is often ignored in 
genetic studies. MHC genetics still requires special expertise to account for 
the special challenges involved. The new MHC genotyping approaches, e.g., 
next-generation sequencing of exomes and transcriptomes and population-
specific SNP-tagging of MHC alleles, will likely offer a more straightforward 
and cost-effective methods for MHC analyses, especially for those not 
familiar with the fascinating MHC region [82,84,95]. It is highly plausible 
that this leads to considerable advancements in understanding the region 
and its associated traits in the years to come.  
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